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CHAPTER 1 
 
Introduction  
 
Schizophrenia is a severe and chronic mental disorder with an incidence of about 0.3–1.0% in the 
human population (Howes and Kapur, 2009). Symptoms of schizophrenia include mainly positive 
symptoms (i.e. hallucinations  and  delusions), negative symptoms (i.e. blunted  affect,  poverty  of  
speech,  curbing  of  interest  and  social withdrawal), and cognitive deficits. The appearance of the 
disorder generally occurs during pubescence/young adulthood, and the time course of the disease is 
characterized by a series of repeated clinical deterioration periods (Weinberger and Harrison, 2011). 
Although the exact pathophysiology of the disease is still unknown, schizophrenia is believed to be a 
multifactorial disorder, with genetics, environmental, psychological, and social factors contributing 
to its etiology and clinical manifestations.  
On the molecular level, in its more traditional postulation, the dopaminergic hypothesis of psychosis 
stated that putative subcortical hyperdopaminergy, stemming from over-activation of meso-striatal 
pathways, may cause productive psychotic symptoms, while a decreased function of the dopaminergic 
neurons belonging to the meso-cortico-limbic tract may explain the cognitive dysfunctions that are 
observed in schizophrenia (Kapur, 2004). The observation that early antipsychotic medications such 
as chlorpromazine and haloperidol shared a capacity to block dopamine D2 receptors corroborated 
this view. However, despite direct evidence supporting a dopaminergic dysfunction in schizophrenia, 
several neurotransmitter systems and functional networks within the brain have been found to be 
affected in this disorder, postulating that dopaminergic dysfunction may not necessarily be a primary 
phenomenon. 
Indeed, abnormalities in glutamate neurotransmissions have nowadays been suggested  as major,  
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albeit  not  unique, players in the pathophysiology of  psychosis (de Bartolomeis et al., 2005; Iasevoli 
et al., 2014b; Javitt and Zukin, 1991; Konradi and Heckers, 2003; Laruelle et al., 2003; Seeman, 
2009). 
 
1.The rise and (partial) fall of the  N-methyl-D-aspartate (NMDA) Receptor Hypofunction 
(NRH) hypothesis of schizophrenia pathophysiology 
One of the first evidence of an altered glutamate system in schizophrenia was provided by a report of 
significantly reduced glutamate levels in schizophrenia patients’ cerebrospinal fluid  (Kim et al., 
1981). Further attention to the glutamatergic system was given after the observation that 
phencyclidine (PCP; angel dust), which is a N-methyl-D-aspartate (NMDA) receptor non-competitive 
antagonist, could exacerbate psychotic symptoms in humans and generate a “schizophrenia-like” 
syndrome in PCP addicts (Javitt, 1987; Rosenbaum et al., 1959). Ketamine, another non-competitive 
NMDA receptor antagonist, was described to induce a psychotic-state in healthy volunteers particularly 
mimicking positive, negative and cognitive symptoms of schizophrenia (Javitt, 2010; Javitt and Zukin, 
1991; Krystal et al., 2003; Krystal et al., 1994), and to exacerbate psychotic symptoms in both drug-free 
schizophrenia patients and in antipsychotic-responder patients (Lahti et al., 1995; Lahti et al., 2001; 
Malhotra et al., 1997). The occurrence of negative symptoms in healthy subjects had not been observed 
in other models of schizophrenia, rendering glutamatergic drugs-induced psychosis the best 
pharmacological model of the disease in all its psychopathological manifestations. Interestingly, animal 
studies showed that acute PCP administration increased both locomotor activity and stereotypic 
motor behaviors (Kesner et al., 1981), whereas sub-chronic PCP administration was reported to 
induce behavioral sensitization  (Jentsch et al., 1998). Moreover, ketamine and other NMDA 
receptor non-competitive antagonists, such as MK-801, were also described to induce similar 
behavioral outcomes (Tricklebank et al., 1989). A part from the effects on the locomotor behavior, 
these compounds were also found to impair animal behaviors reminiscent of cognitive tasks in 
humans (Verma and Moghaddam, 1996). Altogether, the biochemical and behavioral studies quoted 
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above were the basis for the Olney and Farber model of psychosis,  known as the NMDA receptor 
hypofunction (NRH) hypothesis (Olney et al., 1999). Thus, the administration of non-competitive 
NMDA receptor  antagonists such as ketamine has been suggested  as a powerful preclinical model of 
psychosis, with substantial heuristic properties to study both molecular targets in psychosis 
pathophysiology and novel therapeutic strategies (Lipska and Weinberger, 2000). Accordingly, the 
administration of antipsychotic agents in preclinical settings was found to revert behavioral 
alterations caused by non-competitive NMDA receptor antagonists (Corbett et al., 1995; Johansson 
et al., 1994).  
Specifically, the NRH hypothesis implied that glutamatergic alterations in schizophrenia, starting 
from a reduced NMDA receptor activity, would perturb a number of glutamatergic and non-
glutamatergic systems and NMDA receptor hypo-functionality became widely accepted as the 
primary lesion leading to a complex cortical-subcortical perturbation in several neurotransmitter 
systems (Olney and Farber, 1995; Olney et al., 1999). Many efforts were therefore spent in the 
search of molecular abnormalities primarily in the number and distribution of glutamate receptors in 
key brain regions of schizophrenia patients, but the results obtained are still contradictory (Beneyto 
et al., 2007; Beneyto and Meador-Woodruff, 2008; Clinton et al., 2003; Corti et al., 2007; Gupta et 
al., 2005; Lyddon et al., 2012; McCullumsmith et al., 2007; O'Connor and Hemby, 2007; O'Connor 
et al., 2007; Richardson-Burns et al., 2000; Weickert et al., 2013). Significant discrepancies remain 
over the role of glutamate receptor abnormalities in schizophrenia patients—discrepancies most 
likely due to methodological issues, like limited sample selection and biochemical techniques.  
Thus, the lack of consistent evidence has warranted further research to refine the role of the 
glutamatergic system, shifting the focus on abnormalities in glutamatergic post-receptor molecules 
implicated in neurotransmitter signaling (Coyle et al., 2012). Intriguingly, the post-receptor 
molecules that have been found involved in schizophrenia pathophysiology and responsive to 
antipsychotic drugs  do contribute to glutamatergic signaling and promote the interplay between 
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glutamate receptors and other neurotransmitter systems, mainly the dopaminergic one. Therefore, 
perturbation of the dopamine-glutamate interplay at multiple levels has been proposed to play a 
pivotal role in psychosis pathophysiology. 
 
2. The dopamine-glutamate interplay and the Post-Synaptic Density (PSD) in psychosis 
 
At the subcellular level, the dopamine-glutamate interplay occurs within the Post-Synaptic Density 
(PSD), a specialized matrix that appears as an electrondense thickening located at excitatory post-
synaptic terminals of the glutamatergic synapse (Okabe, 2007). The PSD represents a complex 
protein network devoted to the fine-tuning of signal transduction that integrates synaptic signals from 
presynaptic neurons and different neurotransmitter systems (de Bartolomeis et al., 2005). It has been 
shown that up to four-hundred proteins can be regularly found by mass spectrometry fingerprinting 
in the PSD proteome, including: membrane receptors and channels, scaffold and anchoring proteins, 
signaling proteins, GTPases, kinases, phosphatases and cytoskeleton proteins (Collins et al., 2006; 
Gold, 2012; Sheng and Hoogenraad, 2007). Specifically, NMDA receptors are placed at the core of 
this protein mesh, with non-NMDA ionotropic and metabotropic glutamate receptors located at the 
edge of the ultrastructure (Sheng and Hoogenraad, 2007). In this molecular context, dopamine and 
glutamate signaling pathways cross-talk starting from the receptor level, since it has been found that 
the activation of NMDA receptors favors the recruitment of D1 receptors to the plasma membrane of 
neurons in vitro (Scott et al., 2002). In turns, the activation of dopamine D1 receptors has been found to 
modulate the rapid trafficking of NMDA receptor subunits (Hallett et al., 2006). Moreover, a physical 
interaction leading to the formation of an NMDA/D1 receptor hetero-oligomer has been reported (Lee et 
al., 2002).  At the post-receptor level, many PSD proteins (such as the dopamine- and adenosine 3’,5’ 
monophosphate (cAMP)-regulated phosphoprotein pf 32 kD (DARPP-32), CaMKII, Neuronal Calcium 
Sensor-1 (NCS-1), and calcyon have essential roles in controlling and routing both dopamine and 
glutamate neurotransmission. One relevant effector of dopamine-glutamate interplay within the PSD 
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is the activity-regulated cytoskeleton-associated protein (Arc), which is a highly expressed dendritic 
protein involved in synaptic plasticity (Shepherd and Bear, 2011). Arc has a spectrin homology 
sequence in the C-terminal region and binding sites for endophilin 3 and dynamin 2, interacts with 
proteins involved in clathrin-mediated endocytosis and facilitates the removal of  α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors from the membrane ((Bloomer et al., 2007; 
Chowdhury et al., 2006) and is considered a marker for neuronal plastic changes relevant for learning and 
memory (McIntyre et al., 2005).  
However, recent attention is focused on the scaffold proteins, which constitute a class of PSD proteins 
with multiple functions. Particularly, scaffolding proteins owe a particular role by linking the different 
components of glutamate receptor complexes and by regulating glutamate receptor trafficking and 
therefore modulating the signaling cascade starting from membrane receptors (Figure 1.) (Iasevoli et al., 
2013b; Vessey and Karra, 2007).   
The scaffold protein subsets mostly studied are: 1) the NMDA receptor and type I metabotropic 
glutamate receptor (mGluR1/5) scaffold members of the membrane-associated guanylyl kinase 
(MAGUK) family; 2) the Homer family of proteins; 3) and the ProSAP/Shank (SH3 domain and ankyrin 
repeat-containing protein) family of proteins (Bayes et al., 2011; Iasevoli et al., 2013b). 
The MAGUKs, including PSD-95, SAP102 and PSD-93, contain the PSD-95/disc large/zonula 
occludens-1 (PDZ) domains, which are considered a hallmark of the PSD (Xu, 2011). PDZ domains are 
of fundamental importance since they are peptide-binding domains that allow the above-mentioned 
proteins to interact with a variety of binding partners within the PSD, such as NMDA receptors (Kim and 
Sheng, 2004).Moreover, PSD-95 has been shown to interact with dopamine and glutamate receptors and 
regulate their activation state through its binding domain (Zhang et al., 2009). Therefore, MAGUKs 
participate to the formation of protein multimers within the PSD, providing a physical bridge between 
receptors and intracellular molecules at the crossroad among glutamatergic and dopaminergic signaling 
pathways (de Bartolomeis et al., 2014) 
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Figure 1. 
Figure 1. Postsynaptic density (PSD) proteins elaborate and integrate multiple transductional pathways starting at main dopamine membrane receptors. 
Scaffolding proteins (Homer, Shank, PSD-95) physically connect receptors, linking them to intracellular calcium stores. 
NMDAR, N-methyl-D-aspartate glutamate receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate metabotropic 
glutamate receptor type 1a/5; TARP, transmembrane AMPA receptors regulating protein or stargazin; PSD-95, postsynaptic density DISC1, disrupted 
in schizophrenia 1; GSK3, glycogen synthase kinase 3; PDE4, phosphodiesterase 4; GKAP, guanylate kinase associated protein; H1a, early inducible 
protein; PIP2, phosphatydilinositol bisphosphate; DAG, diacylglycerol; IP3, inositol 1,4,5-trisphosphate; cAMP, cyclic monophosphate; ER, 
endoplasmic reticulum; PLC, phospholipase C; PKC, protein kinase C; PKA, protein kinase A; CAMK, calcium-calmodulin regulated kinase; activated 
protein kinases; Erk, extracellular signal-regulated kinase; MEK, MAPK/Erk kinase; and Rac1, Ras-related C3 botulinum toxin substrate 1. 
 
The second most studied PSD scaffold family of proteins is the Homer one, whose products are 
encoded by three distinct genes (Homer 1, 2, 3), providing both constitutive (Homer1b/c, Homer2a/b, 
Homer3) and inducible (Homer1a and ania-3) isoforms (de Bartolomeis and Iasevoli, 2003; 
Shiraishi-Yamaguchi and Furuichi, 2007). Through a conserved N-terminal Ena-VASP-homology 
(EVH1) domain, Homer proteins interact with multiple PSD targets, whereas the C-terminus coiled-
coil (CC) domain mediates homotypic interactions and is required for self-multimerization (Xiao et 
al., 1998), 1998 #166}. Homer long isoforms are constitutively expressed in neurons (Soloviev et al., 
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2000), and have been described to physically bridge mGluRsI to inositol 1,4,5-trisphosphate 
receptors (IP3Rs) (Tu et al., 1998). Moreover, the multimeric Homer clusters may link NMDA 
receptors with mGluRsI via a Shank-guanylate kinase-associated protein (GKAP)- PSD95 complex 
(Tu et al., 1999). Through their EVH1 domain, long Homers may also bind to cytoskeletal 
components, such as filamentous actin and Drebrin, and the de-clustering of Homer complexes in 
response to synaptic activity has been demonstrated to anticipate the synaptic cytoskeletal 
rearrangements (Shiraishi et al., 2003). Moreover, recent evidence demonstrated the role of long 
Homers in forming a polymeric network with other PSD proteins, which is essential to maintain 
dendritic spine structure and to ensure synaptic function (Hayashi et al., 2009). On the other end, the 
short isoform Homer1a is induced in an immediate-early gene (IEG)-like fashion, lacks the CC motif 
and  is unable to multimerize (Bottai et al., 2002). This truncated isoform is induced by several 
synaptic stimuli and act as ‘dominant negative’ by disrupting long Homers constitutive clusters 
(Xiao et al., 1998), thus regulating the scaffolding-process and function of long isoforms finally 
resulting in a modification of synaptic architecture (Sala et al., 2003). Homer1a induction by 
synaptic stimuli has been demonstrated also to impact Ca++ intracellular oscillations, through the 
regulation of long Homers’ coupling with Transient Receptor Potential Channels, IP3Rs, and 
Ryanodine receptors (RyRs) (Worley et al., 2007).  
Finally, the ProSAP/Shank family of proteins is composed by Shank 1, Shank 2, and 
Shank 3, which are considered key PSD scaffolds implicated in modulating glutamate 
neurotransmission (Boeckers et al., 2002; Vessey and Karra, 2007). Particularly, as mentioned before, 
Shank proteins allow the formation of polymeric network complexes that require the assembly of Homer 
tetramers and have been proposed to build functional platforms for other PSD proteins (Hayashi et al., 
2009).Indeed, affinity-purified complexes obtained from PSD fractions have been described to include 2-
amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid (AMPA) receptor subunits (GluR1, GluR2, 
GluR3, GluR4), subunits of the NMDA receptor (NR1, NR2A, NR2B), G protein regulators and 
scaffolds such as PSD-95, Shank 2, Shank 3, and Homers (Dosemeci et al., 2007). 
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Recent findings have demonstrated that PSD proteins contribute substantially to the interaction between 
dopamine and glutamate systems at receptors and post-receptors levels. Specifically, PSD scaffolds are 
thought to modulate dopamine and glutamate receptor trafficking and localization to the surface 
membrane and their reciprocal interaction. For instance,  the scaffold PSD-95 has been found to be 
required for D1 dopamine receptors in order to modulate NMDA currents (Gu et al., 2007), as well as 
PSD-95 has been described to directly regulate NMDA functions by abolishing the NMDA-mediated 
inhibition of D1 receptors internalization (Zhang et al., 2009). 
Intriguingly, stable or transient changes in the number and/or activity of PSD components have been 
suggested to be implicated in the pathophysiology of a number of neuropsychiatric diseases such as 
schizophrenia, but also developmental disorders that present similarities with some schizophrenia 
symptoms domains (Cheng et al., 2010; de Bartolomeis and Iasevoli, 2003; Gardoni et al., 2009; 
Szumlinski et al., 2006). Consequently, it could be speculated that the disruption of post-receptor clusters 
due to PSD dysfunctions may cause complex behavioral deficits (e.g. motor, cognitive deficits) that 
mirror a failure in synaptic plasticity, which has been considered central to schizophrenia 
pathophysiology  (Moreau and Kullmann, 2013; Wiescholleck and Manahan-Vaughan, 2013). For 
example, knock-out mice for Shank1 gene have been reported to exhibit impaired memory functions, 
weaker basal synaptic transmission, reduced number of dendritic spines, and diminished PSD density 
compared to wild-type littermates (Hung et al., 2008). Moreover, these animals have been shown to 
poorly perform in social communication tasks, regarded as animal behavioral correlates of the social and 
communicative impairments commonly associated with schizophrenia (Wohr et al., 2011). Consistently, 
a mutation in the promoter region of Shank1 gene  has been associated with working memory deficits in 
schizophrenia patients in subjects at risk for psychosis (Lennertz et al., 2012). Focusing on the MAGUKs 
family of scaffolds,  the levels of PSD-95 mRNA have been reported differentially altered in several 
brain areas of postmortem tissues from schizophrenia patients compared to healthy subjects (Clinton et 
al., 2003; Ohnuma et al., 2000) and some, although  still conflicting, evidence is accumulating on 
associations between functional polymorphisms  of the DLG4 gene with a genetic susceptibility to 
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schizophrenia (Cheng et al., 2010; Tsai et al., 2007). Other genetic studies have observed a possible 
involvement also of Homer genes in the pathophysiology of schizophrenia. Indeed, an association 
between Homer1 gene polymorphisms and clinical psychopathology assessments in schizophrenia has 
been demonstrated. Two Homer1 polymorphisms (rs2290639 and rs4704560) have been associated with 
scores on Positive and Negative Syndrome Scale (PANSS, a common rating scale for symptoms severity 
assessment in schizophrenia) subscales at baseline (Spellmann et al., 2011). In preclinical settings, 
expression of  Homer1a has been found significantly increased in the striatum in a condition modeling 
NRH, i.e. acute administration of neurotoxic and non-neurotoxic subanesthetic doses of ketamine 
(Iasevoli et al., 2007),  and a series of abnormal behaviors have been observed in an experiment of 
Homer1a RNA interference (RNAi) in rats, which exhibited a significant decrease in Homer1a 
expression in the striatum and hippocampus (Hong et al., 2013). After Homer1a RNAi treatment, it has 
been observed: higher levels of vertical and horizontal activities at the Làt maze, indicating increased 
hyperactivity and non-selective attention; longer latencies before locating the platform and longer total 
swim distances in the Morris water maze (MWM), indicating that Homer1a down-regulation impaired 
attention, learning and memory abilities (Hong et al., 2013)as. Moreover,  Homer1 knock out mice 
exhibit attention deficits and hyperactivity-like behavior, which has been reversed by adeno-virus 
associated delivery of Homer1a in the prefrontal cortex (Lominac et al., 2005). Finally, also the other 
IEG Arc has been found implicated in schizophrenia pathophysiology (Manago et al., 2016), and its 
levels of expression have been demonstrated to be responsive to antipsychotic administration (de 
Bartolomeis et al., 2016; de Bartolomeis et al., 2013b). 
Indeed, our group has observed that gene expression of PSD transcripts may be modulated by 
antipsychotic drugs, implying that the PSD may be centrally involved in the mechanism of action of these 
agents (Iasevoli et al., 2011a; Iasevoli et al., 2010b; Polese et al., 2002; Tomasetti et al., 2007). Indeed, 
through postsynaptic network modulation, antipsychotics  may induce dopamine-glutamate synaptic 
remodeling, which is at the basis of their long-term physiologic effects. 
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Due to the studies conducted so far, showing that PSD components play a key role in synaptic plasticity 
processes, behavioral conducts, and are modulated by antipsychotics,  these molecules are gaining 
relevant interest in order to unveil the final molecular rearrangements at the synapse-level possibly 
implied in old, current and future psychosis treatment strategies. 
 
 
3 .Current antipsychotic drugs and the challenge of non-response: translational implications 
from preclinical studies 
Dopamine D2 receptor blockade  is still regarded as the main condition for antipsychotic activity of a 
compound (Kapur et al., 2000; Mamo et al., 2004; Meisenzahl et al., 2008). Nevertheless, current 
treatments with antipsychotics have been proven effective in curtailing particularly acute symptoms, 
while schizophrenia patients show a large number of unmet needs in terms of negative and cognitive 
symptoms control by available pharmacotherapy. Indeed, an estimated 30% of patients do not 
respond or respond poorly to current treatments (Lindenmayer and Khan, 2004), and only a small 
percentage of responding patients is able to have a normal working life. Indeed, multiple relapses 
still occur frequently (almost 80% of patients within 5 years after initial diagnosis) and even with 
appropriate intervention, treatment responses often wane over a longitudinal timeline (Yin et al., 
2017). This worsening of illness severity in the context of continual antipsychotic exposure may be a 
sign of treatment resistance. Recently,  the Treatment Response and Resistance in Psychosis 
(TRRIP) working group was formed to establish consensus criteria to standardize the definition of 
treatment resistant schizophrenia (TRS) (Howes et al., 2017). As expected, in these guidelines, dose, 
duration of treatment and cognitive impairment were highly considered to play a role in non-
response to antipsychotics (Howes et al., 2017). 
As stated above,  antipsychotics act at different degrees as antagonists at postsynaptic D2 receptors, 
thereby reducing the activation of dopaminergic pathways in the mesostriatal and mesolimbic 
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circuitries. D2 receptors are under dynamic regulation from many kinases and trafficking enzymes 
and neurotransmission can undergo both desensitization and resensitization depending on the 
regulatory mechanisms in play (Beaulieu and Gainetdinov, 2011). Therefore, continual 
administration of antipsychotics may be one of the factors that alter the sensitivity of D2 receptors 
possibly ending in alterations of the signaling cascade. Animal studies have variously reported at the 
behavioral level the effects of chronic administered antipsychotics in rodents. For example, rats pre-
treated with chronic haloperidol and subsequently administered apomorphine several days after 
haloperidol withdrawal,  had greater behavioral supersensitivity—as measured by locomotor tasks—
compared to control rats (Montanaro et al., 1982). Chronic haloperidol pretreatment has also been 
shown to decrease dopamine release in preclinical settings (Lane and Blaha, 1987), whereas 
injections of exogenous dopamine into the nucleus accumbens of rats pretreated with haloperidol 
elicited hypersensitization effects (Halperin et al., 1983). Moreover,  rats pretreated to a low (0.25 
mg/kg) or high (0.75 mg/kg) dose of haloperidol through continuous infusion via osmotic minipump 
receiving injections of amphetamine at fixed time-points after the discontinuation of haloperidol, 
were found to show locomotor activity supersensitivity reminiscent of previous withdrawal studies 
(Samaha et al., 2007). In addition to behavioral tests, assays examining the receptor number and 
affinity of D2 receptors found increases in the high affinity state of D2 receptors for the high dose of 
haloperidol pretreatment (Samaha et al., 2007). Taken together, these findings demonstrate that the 
effectiveness of chronic administration of antipsychotics diminish during the period of receptor 
sensitization. While the mechanism that underlies the development of supersensitivity cannot be 
directly measured using behavioral tasks, it seems likely that post-synaptic signaling regulations of 
the dopamine pathways are affected by chronic antipsychotic administration. As an example, several 
genes linked to dopaminergic signaling were found to be downregulated in the presence of chronic 
antipsychotic treatment (Fatemi et al., 2006). In this context, the study of molecular adaptations that 
may  occur in acute versus chronic administration of antipsychotic compounds can be particularly 
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interesting in order to shed a light on molecular adaptations to the administration of these drugs. 
Early studies from our group demonstrated that in rodents both first and second generation 
antipsychotics may directly impact several PSD molecules and scaffolding proteins via differentially 
inducing their expression pattern in both acute and chronic paradigms of administration (de 
Bartolomeis et al., 2002; Polese et al., 2002). Particularly, the specific perturbation of dopaminergic 
signaling may lead to concurrently specific differential topographical brain expressions of  the 
Homer family of PSD genes directly depending on the receptor profile of the antipsychotic 
(Tomasetti et al., 2007). Therefore, studies on chronic paradigms of antipsychotic administration are 
warranted to model from a translational point of view the conditions of therapy in clinical 
populations and to investigate the plastic changes occurring in the PSD in these settings. 
Other real-word conditions that can have an impact on antipsychotic treatment in terms of clinical 
response by acting as confounding factors may be represented by substance misuse during 
antipsychotic treatment. Apart from alcohol, cocaine or other drugs, the abuse of coffee drinking and 
tobacco smoking is a common addictive conduct in schizophrenia patients, above all among those 
taking antipsychotics (Thoma and Daum, 2013). On the clinical side, the abuse of such legal 
substances in patients has been variously regarded to cause beneficial other negative effects on the 
clinical course of the disease and on the rate of antipsychotic response. Despite this body of evidence, 
however, little is known about the molecular changes induced in synaptic sites by these compounds 
when given in association to antipsychotics. Nevertheless, nicotine and caffeine have been included 
among possible therapeutic strategies for Parkinson’s disease (PD) and may counteract the PD-like 
extrapyramidal side effects of antipsychotics (Oertel and Schulz, 2016). Moreover, both adenosine 
receptors (which are directly modulated by caffeine) and nicotine receptors have been suggested as 
potential targets of pharmacological strategies to address residual symptoms not responding or 
responding poorly to conventional antipsychotics (Marcus et al., 2016; Rial et al., 2014).. 
Intriguingly, several reports exist on the modulation exerted by these substances on PSD molecules. 
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Nicotine has been reported to increase protein levels of the PSD protein Homer1a in HEK-293 cells, 
most presumably as a consequence of reduced proteasome degradation  (Rezvani et al., 2007).  
According to these observation, nicotine exposure significantly increased stability and levels of 
ubiquitinated Homer1a compared with control (Rezvani et al., 2007). These effects may indicate a 
generalized strengthening of glutamatergic activation by nicotine, since they were associated to a 
nicotine-dependent increase of multiple glutamate receptors in mouse prefrontal cortex (Rezvani et 
al., 2007). Moreover, in an early study, acute injection of a high caffeine dose (i.e. 100 mg/kg) was 
reported to significantly increase Arc mRNA expression in the striatum (Dassesse et al., 1999), 
supporting the idea that this compound may have modulatory effects also upon the expression of 
other IEGs. Therefore, it appears appealing to better characterize the molecular and behavioral 
effects of caffeine and nicotine in addition to haloperidol on key molecules implied in synaptic 
plasticity processes such as the ones belonging to the PSD.   
Finally, it is nowadays widely accepted that current pharmacotherapeutic strategies do not effectively 
treat the cognitive deficits of schizophrenia (Dunlop and Brandon, 2015; Karam et al., 2010). 
Cognitive dysfunction has been increasingly recognized as a core feature of schizophrenia; 90% of 
patients show deficits in at least one cognitive domain, including working memory, attention, processing 
speed,  problem solving, social cognition, visual learning and memory, and verbal learning and memory 
(O'Tuathaigh et al., 2017) . Despite considerable heterogeneity (Weinberg et al., 2016),  the severity of 
these symptoms at the early stage of illness represents a significant prognostic indicator of clinical course 
and functional outcomes (de Bartolomeis et al., 2013a; Green, 2006). Moreover, cognitive dysfunctions 
may play a role in TRS occurrence or generally in poor responders (de Bartolomeis et al., 2013a).  
Significant obstacles to developing effective and novel cognitive enhancing therapies have included lack 
of clarity regarding the neural circuitry and molecular/cellular changes underlying cognitive dysfunction 
in schizophrenia (Cope et al., 2016; Tandon et al., 2009). Despite the complexity of cognitive 
impairment pathophysiology, glutamatergic dysfunctions together with  reduced dopamine 
neurotransmission in medial prefrontal cortex have been considered major causative abnormalities 
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(Abi-Dargham and Moore, 2003; Gaspar et al., 2012). Indeed, agents stimulating NMDA receptors 
together with mGluRI antagonists have received the most attention among potential compounds 
targeting glutamatergic dysfunction in the effort of impacting also cognitive symptoms of the disease 
(Alberati et al., 2012; Chaki and Hikichi, 2011; Satow et al., 2008). 
The recent observation that PSD proteins are modulated by anti-dopaminergic compounds 
commonly used in schizophrenia therapy but also by agents that modulate glutamatergic  
neurotransmission (Iasevoli et al., 2007), has further reinforced interest in these molecules. The 
effects of antipsychotics on PSD molecules are so specific that the topographical pattern of PSD 
genes expression may vary with the dose of the antipsychotic administered: indeed, increasing doses 
of selected first or second generation antipsychotic may progressively recruit the expression of 
crucial PSD genes, such as Zif268, Homer1a, Arc, while gradually impacting selected brain areas (de 
Bartolomeis et al., 2015). Moreover, the common clinical practice of switching antipsychotic has 
been demonstrated to specifically perturb PSD molecules depending on the specific switch procedure 
(de Bartolomeis et al., 2016). On the other hand, ketamine, MK-801 and the non-competitive NMDA 
receptor antagonist memantine have been found to exert divergent effects on PSD transcripts, 
reinforcing the idea that compounds impacting glutamatergic signaling may also modulate 
differentially these plasticity linked molecules (de Bartolomeis et al., 2013c; de Bartolomeis et al., 
2012).  
Since PSD molecules may represent an intracellular hub where dopamine and glutamate modulate 
one another reciprocally, targeting these molecules may appear to be beneficial in schizophrenia 
therapy, especially in the treatment of resistant conditions where conventional antipsychotic 
therapies fail to fully control symptoms. 
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CHAPTER 2 
 
Aim of the Research 
 
The possibility to translate real-world practice treatment strategies in psychosis to preclinical settings 
gives the opportunity to dissect at a molecular level the putative modifications that occur and concur 
to synaptic plasticity rearrangements. As already pointed-out, dopamine-glutamate interplay 
dysfunctions have been suggested as key factors in psychosis pathophysiology and for the 
most part, synaptic interactions between dopamine and glutamate signaling pathways take part at the 
PSD. Therefore, the major goal of the present research was to focus on PSD adaptations to 
pharmacological manipulations mimicking common clinical situations.  
According to these premises, here we provide a set of preclinical studies whose aim was to 
investigate: i) the postsynaptic molecular adaptations to prolonged pharmacological treatments with 
the specific scope of comparing novel multitargeting agents to first and second generation 
antipsychotics currently used in clinical practice; ii) the comparison of acute versus chronic 
plasticity-related genes differences in terms of expression as a molecular fingerprint of the two 
different treatment situations; iii) the molecular effects on key PSD molecules of the combined 
assumption of voluptuary substances such as caffeine and nicotine plus antipsychotics; iiii) the 
adaptations of PSD transcripts to novel proposed add-on treatment options to antipsychotics, and 
particularly to the administration of minocycline.  
With the first set of experiments, particular efforts were made at recreating current pharmacological 
strategies focusing on newly approved antipsychotic agents that may activate postsynaptic transcripts 
with a different topographic distribution from that elicited by standard therapies, and that may 
suggest better clinical efficacy or possibly some new adverse effects. This study was followed by the 
second set of experiments, with the specific aim of  providing a direct head-to-head comparison of 
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the synaptic molecular changes caused by acute versus chronic administration of the same 
compounds focusing on the IEG Homer1a.  
The third set of experiments, through topographic analyses and a behavioral study,  was aimed at 
providing the  differential region-specific brain gene expression changes that may occur when 
antipsychotics are taken with nicotine and caffeine, whose positive or negative additive effects are 
still a matter of debate at the clinical level. 
Finally, since glutamatergic agents have been considered as potentially relevant add-on strategies to 
antipsychotics in order to reduce negative symptoms and improve cognition, the last set of 
experiments was aimed at dissecting the molecular effects of the synthetic second-generation 
tetracycline minocycline that has been recently suggested for the treatment of schizophrenia. Indeed, 
several lines of evidence suggest that this antibiotic may exert glutamatergic modulatory and anti-
inflammatory effects, which are consistent with a potential implication of inflammatory and 
oxidative pathways in the pathophysiology of psychosis. 
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CHAPTER 3 
 
Materials and Methods 
 
Animals 
 
Male Sprague-Dawley rats with a mean weigh tof  250 gr. were obtained from Charles-River 
Laboratories (Lecco, Italy). Animals were housed and allowed to adapt to human handling in a 
temperature and humidity controlled colony room with 12/12 h light–dark cycle (lights on from 
06:00–18:00) with ad libitum access to chow and water. All procedures were conducted in 
accordance with the National Institute of Health (NIH) Guide for Care and Use of Laboratory 
Animals (NIH Publication No. 82-23, revised 1996) and were approved by local Animal Care and 
Use Committee. All efforts were made to minimize animal suffering. 
 
Drugs 
Asenapine powder (gently supplied by H. Lundbeck A/S, Copenaghen, Denmark) and olanzapine 
powder (Sigma-Aldrich, Milan, Italy)  were dissolved in saline solution (NaCl 0.9%).  
Haloperidol was provided as an injectable solution (Lusofarmaco, Milan, Italy) and then diluted at 
experimental doses. 
Caffeine powder (Sigma-Aldrich, Milan, Italy), (-)nicotine hydrogen tartrate salt powder (Sigma-
Aldrich, Milan, Italy), and GBR-12909 dihydrochloride powder (Sigma-Aldrich, Milan, Italy) were 
dissolved in saline solution (NaCl 0.9%). 
Minocycline and ketamine (Sigma-Aldrich, St. Louis, MS, USA) were supplied as a powder and 
dissolved in saline solution  (NaCl 0.9%).  
All solutions were adjusted to physiological pH value and injected i.p.at a final volume of 1 ml/kg, 
according to internationally approved protocols (Turner et al., 2011). 
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In situ hybridization 
Radioactive in situ hybridization was performed according to previously published protocols 
(Ambesi-Impiombato et al., 2003). Animals were killed by decapitation and brains were quickly 
removed, frozen on powdered dry ice and stored at -70°C prior to sectioning. Serial brain coronal 
sections of 12µm were cut on a cryostat set at a temperature of -18°C from Bregma -1.20mm to -
1.00mm, using the rat brain atlas of Paxinos and Watson as an anatomical reference (George Paxinos, 
2001). Sections were thaw-mounted on to gelatin-coated slides and stored at -70°C for subsequent 
analysis. Probes used for radioactive in situ hybridization were oligodeoxyribonucleotides 
complementary to mRNA sequences of target  genes (MWG Biotech, Firenze) and were designed 
from Gen-Bank sequences and checked with BLAST in order to avoid cross-hybridization. For each 
probe, a 50 µl labeling reaction mix was prepared on ice using DEPC-treated water, 1X tailing buffer, 
7.5 pmol/µl of oligodeoxyribonucleotide, 125 units of terminal deoxynucleotidyl transferase (TdT) 
and 100 mCi 35 S-dATP. Unincorporated nucleotides  were separated from radiolabeled DNA using 
ProbeQuant G-50 Micro Columns  (Amersham- GE Healthcare Biosciences, Milano, Italy). Sections 
were fixed in 4% formaldehyde in 0.12 M PBS (pH 7.4), quickly rinsed three times with PBS,  
placed in 0.25% acetic anhydride in 0.1 M triethanolamine/0.9% 25 NaCl, pH 8.0, for 10 min and 
then dehydrated in 70%, 80%, 95% , 100% ethanol, delipidated in chloroform for 5 min, rinsed again 
in 100% and 95% ethanol and finally air-dried. Sections were hybridized with 0.4-0.6x106 2 cpm of 
radiolabeled  oligonucleotide in a buffer containing 50% formamide, 600 mM NaCl, 80 mM Tris-
HCl (pH 4 7.5), 4 mM EDTA, 0.1% pyrophosphate, 0.2 mg/ml heparin sulfate, and 10% dextran 5 
sulfate. Slides were incubated at 37°C in a humidified  chamber for 22-24 h. Section were 
subsequently washed in 2x SSC/50% formamide at 43-44°C, and then in 1X SSC at room 
temperature. Finally, sections were dried and exposed to a Kodak- 10 Biomax MR auto-radiographic 
film (Sigma), and a slide containing a scale of 16 known amounts of 
14
 C standards (ARC-146C, 
American Radiolabeled Chemical) was co-exposed. The auto-radiographic films were exposed in a 
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time range of 14-30 days. The optimal time of exposure  was chosen to maximize signal-to-noise 
ratio but to prevent optical density from approaching the limits of saturation. Film development 
protocol included a 1.5-minute dip in the developer solution and 3 minutes in the fixer solution. The 
quantitation of the autoradiographic signal was performed using a computerized image analysis 
system, including: a transparency film scanner (Microtek Europe B. V., Rotterdam, The Netherlands), 
an Apple iMac and an ImageJ software (v. 1.50, Rasband, W.S., http://rsb.info.nih.gov/ij/). Brain 
sections on films were captured individually. Scanned images were showed in inverted look-up table 
(LUT) color, although all the other original characteristics (i.e. contrast, brightness, resolution) were 
preserved. All hybridized sections were exposed on the same sheet of X-ray film. Signal  intensity 
analyses were carried out on digitized autoradiograms measuring mean optical density within the 
outlined regions of interest (ROIs)  corresponding to rat brain subregions of the cortex, caudate-
putamen, and nucleus accumbens (Figure 2.).  
 
 
Figure 2. 
Figure 2. Regions of interest (ROIs). This picture reports the ROIs, where gene expression has been quantitated.  
 
 
Regions of interest (ROIs). This 
picture reports the ROIs, 
where gene expression has been 
quantitated. ACC: anterior 
cingulate 
cortex; CAb: core of the nucleus 
accumbens; CP-DL: dorsolateral 
caudateputamen; 
CP-DM: dorsomedial caudate-
putamen; CP-VM: ventromedial 
caudateputamen; 
CP-VL: ventrolateral caudate-
putamen; IC: insular cortex; 
MAC: 
medial agranular cortex; MC: 
motor cortex; SAb: shell of the 
nucleus 
accumbens; SS: somatosensory 
cortex. 
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ROIs were selected based on data describing functional and anatomical correlation between cortical 
and striatal subregions (Willuhn et al., 2003). 
 
 
Studies from our laboratory have demonstrated that these ROIs are key motor-related and limbic-
related regions for evaluating gene expression, with putative translational value (Buonaguro et al., 
2017b; Tomasetti et al., 2011). Measurements of  optical density within ROIs were converted into 
“relative dpm” using a calibration curve based on the standard scale co-exposed to the sections. 14 C 
standard values from 4 through 12 were previously cross-calibrated to 35 S brain paste standards. In 
order to obtain a calibration curve for each X-ray film, a “best fit” 3rd degree polynomial was used. 
For each animal, measurements from 4 adjacent sections were averaged and the final data reported in 
relative dpm as mean ± S.E.M. The whole in situ hybridization procedure was performed blinded 
with coded frozen brains. To test for inter-observer reliability, an independent quantitation was 
performed by a second investigator. Results were considered reliable only when the statistical 
significance of effects obtained by the second investigator was quantitatively consistent with the 
results obtained by the first investigator. 
 
Western Blot  
Rat brains stored at -70°C were dissected on ice to isolate the striatum, which was placed in 1.5ml 
tubes and treated with Thermoscientific SynPER Synaptic Protein Reagent ™ (10ml per gram of 
tissue, protease inhibitors added immediately before use), and then homogenated in a dounce tissue 
grinder. The obtained homogenates were rapidly transferred to appropriate centrifuge tubes and 
centrifuged at 1200g for 10 minutes at 4°C. The supernatant was transferred to new tubes and 
centrifuged at 15000g for 20 minutes at 4°C. Protein amount was measured by Bradford sampling 
and then 2ml SynPER Reagent per gram of tissue was added for storage at -70°C in 5% (v/v) DMSO 
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for subsequent analyses. An amount of 4μg/μl protein per each experimental group was run in wells 
using Bio-Rad Mini-PROTEAN® system, mixed to equal amount v/v of Laemmli ™ buffer for 
visualization and separated on SDS-PAGE 10% polyacrylamide gel. Proteins were transferred on 
nitrocellulose membranes (Amersham Hybond-ECL, GE Healthcare) and blocked in blocking buffer 
(5% nonfat dry milk in PBS and 0.1% Tween 20) for 1 h. The blots were incubated in primary rabbit 
polyclonal antibody for rat Homer1 (Merck Millipore) 1:2000, primary rabbit polyclonal antibody 
for rat Arc (Synaptic Systems) 1:2000 and primary monoclonal anti-actin antibody produced in 
mouse 1:1000 (Sigma-Aldrich) at 4°C overnight. This was followed by appropriate washes in TBS 
and 1 h incubation in a goat horseradish peroxidase-linked anti-rabbit and rabbit anti-mouse 
secondary antibodies respectively (Sigma-Aldrich). Blots were developed with LiteABlot® Extend 
chemiluminescent substrate (EuroClone) and exposed on Fujifilm® western blot films.  
The quantitation of the signal was performed using a computerized image analysis system by ImageJ 
software. Signal intensity by each band  was relativized by dividing per the corresponding standard 
band (the β-Actin band). Data were reported in relative intensity as means ± S.E.M.  
 
Locomotor Activity  
Activity for each animal was filmed in transparent plastic cages (210 square inches floor) with a 
computerized photo camera system (Apple computer ™) and it was measured using a motion capture 
system that simultaneously labeled and tracked movements of each rat (Kinovea®). Three rats were 
placed in each cage and a cage corresponded to a specific treatment group. Motion was calculated 
using centimeters walked through in continuous shot considered as the dependent variable for total 
activity measurement. Locomotor activity following each treatment administration was measured for 
a period of 5 minutes, as in previous established protocols  (de Bartolomeis et al., 2015). Distance 
walked through by each rat was averaged with the others belonging to the same treatment group and 
expressed as centimeters walked through ± S.E.M.  
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CHAPTER 4 
Re-arrangements of gene transcripts at glutamatergic synapses after chronic treatments by 
different doses of antipsychotics with distinct receptor profile  
 
1.Rationale 
 
To reproduce chronic antipsychotic treatment paradigms in preclinical settings is considered of 
valuable translational meaning since they may more closely mimic real-world therapeutic approaches 
and are supposed to produce the synaptic changes occurring during prolonged treatments (Kontkanen 
et al., 2002). Indeed, putative brain structural changes after chronic antipsychotic treatments have not 
been completely described yet. In the context of chronic treatments, another common prescribing 
practice is to prescribe the same compound at different doses . This observation rises the issue of  
understanding how antipsychotics with different receptor profiles and at different doses may impact 
brain plasticity processes (Ho et al., 2011; Vita et al., 2015). 
To do so, we evaluated the expression of key PSD transcripts, i.e. Homer1a, Arc, Homer1b, PSD-95, 
and Shank (details for oligodeoxyribonucleotide probes have been listed in Table 1.) in rat brain 
selected ROIs  after chronic administration of: i) haloperidol, which is considered the prototype of 
first generation antipsychotics and has a relatively selective D2 receptor profile (Correll, 2010); ii) 
olanzapine, a second generation antipsychotic with  a broad multi-receptor profile (Correll, 2010); 
and iii) asenapine, the novel multi-receptor targeting antipsychotic with dopamine D1 and D2 
receptor blockade ratio of approximately 1 (Shahid et al., 2009).  
Probe cDNA length (bp) cDNA position mRNA Gen-Bank# 
Homer1a 48 2527–2574 Homer1a U92079 
Homer1b/c 48 1306–1353 Homer1b/c AF093268 
Arc 45 789-833 Arc NM019361 
Shank 48 2757–2804 Shank1 AF131951 
PSD-95 48 225–269 PSD-95 M96853 
Table 1. 
Table 1. Probes for in situ hybridization histochemistry. 
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The rationale of comparing the above mentioned compounds comes from the observation that current 
antipsychotic development strategies have focused on compounds acting on multiple selected targets 
in order to mainly avoid motor side effects and  produce increased efficacy in treating negative and 
cognitive symptoms (Roth et al., 2004).  
The newly developed antipsychotic which responds to these “multitargeting” strategies is asenapine, 
which shows a binding affinity profile for all serotonergic receptors, equal affinity for D2 and D1 
receptors, as well as for alpha adrenergic receptors, and no affinity for muscarinic receptors (Shahid 
et al., 2009). Thanks to its unique multi-receptor profile, asenapine may differentially impact 
dopaminergic, noradrenergic, serotonergic and glutamatergic neurotransmission: it specifically 
enhances the dopamine bursts from ventral tegmental area (VTA) to the medial prefrontal cortex and 
the nucleus accumbens; regulates noradrenaline signaling from locus coeruleus to the cortex; 
promotes serotonin release in the cortex; enhances glutamate NMDA-mediated currents in pyramidal 
cortical neurons, while it decreases NMDA receptor activity in caudate-putamen and nucleus 
accumbens (Franberg et al., 2009; Franberg et al., 2008; Tarazi et al., 2010). Finally, asenapine 
administered at different doses may exert brain region-specific differential effects on dopamine, 
serotonin and glutamate receptors (Tarazi et al., 2008, 2010).  
Considering that PSD molecules represent crucial crossroads for multiple receptor signaling involved 
in the mechanisms of action of the most frequently used psychotropic drugs and that a direct head-to-
head comparison of the molecular effects of first and second-generation antipsychotics 
at different doses in a chronic paradigm can be of translational value, we tried to address the 
following questions: 
1. Do prototypical first, second generation antipsychotics and newly developed antipsychotics 
induce unique changes in the expression of PSD transcripts with respect to cortical/sub-
cortical brain regions in a chronic paradigm of administration? 
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2. Are there different expression profiles of PSD transcripts in selected ROIs secondary to the 
dose of the antipsychotic chronically administered? 
3.  Is it possible that antipsychotics with different receptor profile or that different doses of the 
same antipsychotic may produce an imbalance of  the Homer1 isomers (i.e. Homer1a and 
Homer1b) relative ratio of transcript expression, considering that those isoforms have been 
described to exert opposite molecular effects (Kammermeier, 2008)? 
In the present study, rats were randomly assigned to one of the following treatment groups (n = 5 for 
each group): control group receiving vehicle (NaCl 0.9%, VEH); haloperidol 0.25 mg/kg (HAL0.25); 
haloperidol 0.5 mg/kg (HAL0.5); haloperidol 0.8 mg/kg (HAL0.8); asenapine 0.05 mg/kg 
(ASE0.05); asenapine 0.1 mg/kg (ASE0.1); asenapine 0.3 mg/kg (ASE0.3); olanzapine 2.5 mg/kg 
(OLA). All drugs were given at behaviorally active doses, based on previous works (Huang et al., 
2008; Iasevoli et al., 2010a; Marston et al., 2009; Tomasetti et al., 2007). The above-listed drugs 
were administered once a day for twenty-one consecutive days. All animals received the drugs in one 
i.p. injection a day. Care was taken to carry out injections at the same hour of the day, every day.  
ANOVA (One-way Analysis of Variance) was used to analyze treatment effects. The Student-
Newman-Keuls (SNK) post-hoc test with the Bonferroni correction was used for groups' comparison. 
In all tests, significance was set at p<0.05. To calculate the Homer1a/Homer1b ratio, signal intensity 
of Homer1a and Homer1b mRNA expression by each antipsychotic compound was normalized on 
values of vehicle mRNA expression (de Bartolomeis et al., 2013c). The Student's t-test was then 
used to compare normalized Homer1a vs. Homer1b mRNA levels by each antipsychotic in each ROI. 
The statistical analyses were performed using JMP9.0.1 software. 
 
2.Results 
The main result of the present study was that chronic treatments with prototypical first and second 
generation antipsychotics compared to the newly developed drug asenapine triggered a complex, 
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antipsychotic- and dose-specific set of re-arrangements in PSD gene transcripts known to be key 
players in structural and functional plasticity processes (Representative autoradiograms of gene 
expression were shown in Figure3.). 
Results are listed for each gene as the expression differences obtained comparing the antipsychotic 
taken into account versus the control group, followed by intragroup differences among the different 
doses of haloperidol and asenapine considered. Finally, the intergroup differences in the expression 
of each gene has been obtained comparing haloperidol versus asenapine, asenapine versus 
olanzapine and haloperidol versus olanzapine –administered groups.   
 
 
Figure 3. 
Figure 3. Autoradiographic film images of Homer1a, Homer1b, Arc, PSD-95 and Shank1mRNA detected bymeans of in situ hybridization 
histochemistry in coronal brain sections after chronic treatment with vehicle (NaCl 0.9%, VEH), haloperidol 0.8 mg/kg (HAL0.8), haloperidol 0.5 
mg/kg (HAL0.5), haloperidol 0.25 mg/kg (HAL0.25), asenapine 0.3 mg/kg (ASE0.3), asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05 mg/kg (ASE0.05), 
olanzapine 2.5 mg/kg (OLA). Blue to red labeling identifies increasing signal intensity levels. 
 
 
2.1 Homer1a 
2.1.1. Gene expression differences between antipsychotic-administered groups and control 
group. 
In the cortex, Homer1a expression was significantly reduced by HAL0.8, HAL0.25 and by ASE0.1 
administration (Figure 4., Table 2.). In the striatum, HAL0.5 and HAL0.8 significantly induced 
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Homer1a mainly in the dorsal and ventro-lateral caudate putamen (Figure 4., Table 2.). Homer1a 
mRNA levels were significantly induced only in the dorso-lateral caudate putamen by ASE0.05 
administration. Olanzapine was found to affect gene expression only in the dorso-lateral region of 
the caudate putamen and in the shell of the nucleus accumbens (Figure 4.,Table 2.).  
 
2.1.2. Haloperidol intragroup gene expression differences. 
The different doses of haloperidol considered in this study affected Homer1a mRNA expression only 
in the MAC region of the cortex and in the shell of the nucleus accumbens (Figure 5.). Specifically, 
HAL0.5 induced significant higher levels of Homer1a gene compared to haloperidol administered at 
higher and lower doses (Figure 5.). 
 
2.1.3. Asenapine intragroup gene expression differences.   
In  the MAC and SS cortical regions, Homer1a expression was significantly induced at a higher 
extent by ASE0.05 compared to ASE0.1 (Figure 5.).  
 
2.1.4. Asenapine vs. Haloperidol gene expression differences. 
Homer1a mRNA levels were found significantly affected in cortical regions mainly in the ASE0.05 
treated group compared to haloperidol administered at high and low doses (Table 3.). Conversely, in 
the striatum, Homer1a  expression levels were significantly higher in the haloperidol treated groups 
compared to asenapine treated groups (Table 3.).   
 
2.1.5. Asenapine vs. Olanzapine gene expression differences.  
Olanzapine was found to induce significantly higher levels of Homer1a mRNA compared to ASE0.1 
in both cortical and striatal regions (Table 4.).  
 
2.1.6. Haloperidol vs. Olanzapine gene expression differences.  
Olanzapine was found to induce significantly higher levels of Homer1a mRNA compared to 
haloperidol treated groups only in cortical regions and mainly in the MAC region (Table 5.).  
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Figure 4. 
Figure 4. Homer1a, Homer1b, Arc, PSD-95 and Shank1 gene expression patterns in cortical and subcortical regions by haloperidol 0.8 mg/kg 
(HAL0.8), haloperidol 0.5 mg/kg (HAL0.5), haloperidol 0.25 mg/kg (HAL0.25), asenapine 0.3 mg/kg (ASE0.3), asenapine 0.1 mg/kg (ASE0.1), 
asenapine 0.05 mg/kg (ASE0.05), olanzapine 2.5 mg/kg (OLA). 
Black label: increased expression vs. VEH at the Student-Newman-Keuls (SNK) post-hoc test with Bonferroni correction (p b 0.05). Blue label: 
decreased expression vs. VEH at the Student-Newman-Keuls (SNK) post-hoc test with Bonferroni correction (p b 0.05). 
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  relative d.p.m. ± S.E.M. ANOVA 
 ROIs VEH HAL0.8 HAL0.5 HAL0.25 ASE0.3 ASE0.1 ASE0.05 OLA F df p 
Homer1a 
AC 
73.72 ± 
6.33 
61.47 ± 
2.66 
78.99 ±  
5.21 
67.64 ±  
3.11 
80.91 ±  
4.74 
77.35 ± 
2.92 
84.52 ± 
5.57 
90.20 
± 4.80 
4.09 7,22 0.0051 
M2 
94.75 ±  
6.39 
69.18 ± 
2.80 
86.31 ± 
1.61 
81.16 ± 
6.28 
91.18 ± 
2.29 
90.53 ± 
1.07 
98.61 ± 
1.16 
102.38 
± 2.89 
11.73 7,22 <.000 
M1 
103.18 
±  7.63 
83.71 ± 
2.32 
97.99 ± 
2.82 
84.88 ± 
6.47 
94.93 ± 
1.72 
87.86 ± 
1.92 
106.88 ± 
2.50 
107.99 
± 3.40 
7.33 7,22 0.0001 
SS 
95.27 ±  
6.06 
85.70 ± 
4.73 
95.65 ± 
3.83 
82.61 ± 
6.46 
90.49 ± 
1.91 
81.91 ± 
3.16 
97.61 ± 
2.07 
101.88 
±  1.09 
3.93 7,22 0.0063 
I 
97.29 ± 
5.37 
76.01 ± 
5.48 
86.08 ± 
5.70 
77.48 ± 
9.46 
79.78 ± 
2.11 
75.17 ± 
4.62 
92.18 ±  
2.07 
96.50 
±  3.00 
3.54 7,22 0.0106 
dm 
75.11 ± 
6.57 
79.81 ± 
6.70 
94.23 ± 
3.75 
84.18 ± 
4.23 
80.29 ± 
2.95 
74.75 ± 
2.85 
87.15 ± 
2.05 
87.61 
± 4.51 
2.71 7,21 0.0358 
dl 
75.72 ± 
7.16 
96.25 ± 
7.45 
102.88 
± 2.78 
92.52 ± 
0.78 
87.59 ± 
1.54 
85.02 ± 
3.46 
100.95 ± 
2.39 
95.76 
± 5.76 
4.27 7,21 0.0044 
vm 
84.61 ± 
7.70 
87.39 ± 
2.17 
95.85 ± 
5.33 
83.45 ± 
3.81 
80.35 ± 
2.38 
82.38 ± 
3.81 
90.06 ±  
1.53 
87.23 
± 4.37 
 7,21 ns 
vl 
78.68 ± 
7.81 
104.04 
± 5.35 
104.89 
± 4.83 
86.96 ± 
3.17 
84.62 ± 
0.47 
74.64 ± 
5.12 
87.17 ± 
2.04 
95.79 
± 4.55 
6.23 7,21 0.0005 
core 
66.68 ± 
4.12 
76.52 ± 
4.05 
82.59 ± 
4.01 
73.90 ± 
7.94 
72.09 ± 
3.69 
67.98 ± 
1.35 
74.77 ± 
4.49 
82.42 
± 4.52 
 7,21 ns 
shell 
56.33 ± 
3.25 
71.49 ± 
1.54 
87.45 ± 
5.38 
65.88 ± 
4.54 
67.29 ± 
1.57 
64.09 ±  
3.32 
70.59 ± 
6.25 
79.40 
± 6.12 
4.29 7,21 0.0043 
 
Homer1b 
AC 
90.98 ± 
2.73 
85.09 ± 
0.95 
87.44 ± 
4.70 
87.28 ± 
2.75 
91.65 ± 
1.98 
88.18 ± 
1.46 
96.32 ±  
2.18 
93.41 
±  3.09 
 7,27 ns 
M2 
91.60 ± 
2.26 
84.09 ± 
0.66 
93.76 ± 
1.09 
86.03 ± 
2.19 
89.18 ± 
0.86 
86.62 ± 
0.71 
95.91 ± 
1.55 
94.97 
± 2.49 
7.51 7,27 <.0001 
M1 
91.16 ± 
2.96 
84.74 ± 
0.78 
93.92 ± 
1.76 
88.61 ± 
3.05 
90.08 ± 
1.11 
87.71 ± 
1.48 
97.89 ± 
1.45 
93.63 
± 2.53 
4.59 7,27 0.0017 
SS 
89.88 ± 
3.11 
84.44 ± 
1.61 
87.34 ± 
5.04 
88.70 ± 
2.71 
92.37 ± 
2.54 
85.98 ± 
2.12 
97.44 ± 
2.03 
92.22 
± 2.28 
2.52 7,27 0.0389 
I 
91.15 ± 
3.26 
86.64 ± 
1.39 
90.33 ± 
4.31 
91.29 ± 
2.871 
93.94 ± 
1.81 
86.79 ± 
2.57 
98.14 ± 
2.30 
97.83 
± 1.77 
3.17 7,27 0.0138 
dm 
88.89 ± 
0.64 
80.60 ± 
1.15 
89.23 ± 
1.04 
84.47 ± 
2.24 
87.76 ± 
1.36 
83.20 ± 
1.05 
91.45 ± 
0.98 
92.49 
± 2.08 
8.86 7,27 <.0001 
dl 
90.89 ±  
1.20 
82.75 ± 
1.14 
89.71 ± 
3.44 
87.54 ± 
2.48 
91.60 ± 
1.64 
87.54 ± 
1.85 
96.64 ± 
2.41 
98.17 
± 2.21 
6.03 7,27 0.0003 
vm 
91.42 ± 
0.37 
82.02 ± 
0.77 
92.10 ± 
0.85 
87.16 ± 
2.74 
89.32 ± 
1.01 
86.15 ± 
1.33 
93.48 ± 
1.39 
95.08 
± 1.70 
9.85 7,27 <.0001 
vl 
93.69 ± 
0.50 
85.71 ± 
1.68 
93.46 ± 
3.78 
90.26 ± 
3.22 
93.04 ± 
1.95 
87.90 ± 
1.50 
97.49 ± 
1.85 
101.29 
± 1.96 
5.66 7,27 0.0004 
core 
89.08 ± 
1.24 
82.45 ± 
0.72 
90.21 ± 
3.54 
87.68 ± 
2.48 
89.46 ± 
1.27 
86.39 ± 
1.92 
95.12 ± 
1.52 
91.07 
± 4.12 
2.53 7,27 0.0383 
shell 
87.82 ± 
0.75 
81.64 ± 
1.02 
93.74 ± 
3.11 
87.65 ± 
2.15 
88.19 ± 
0.64 
84.39 ± 
2.14 
95.12 ± 
1.37 
95.16 
± 0.77 
10.37 7,27 <.0001 
 
Arc 
AC 
111.44 
± 10.33 
78.47 ± 
1.22 
106.28 
± 4.06 
70.99 ± 
5.31 
84.87 ± 
11.09 
94.82 ± 
5.90 
85.63 ± 
12.79 
56.46 
± 2.27 
4.81 7,19 0.0029 
M2 
192.34 
± 20.42 
89.98 ± 
3.76 
123.79 
± 15.01 
106.18 ± 
12.72 
130.34 
± 19.00 
161.38 
± 15.40 
151.82 ± 
17.78 
87.41 
± 4.07 
5.97 7,19 0.0009 
M1 
188.19 
± 14.67 
83.44 ± 
2.98 
112.38 
± 10.62 
98.07 ± 
11.45 
106.49 
± 10.17 
133.72 
± 12.44 
149.66 ± 
21.15 
83.68 
± 6.47 
9.80 7,19 <.0001 
SS 
188.06 
± 18.23 
80.69 ± 
2.62 
102.37 
±  2.10 
106.16 ± 
21.86 
100.12 
± 8.12 
123.28 
± 11.66 
147.78 ± 
10.57 
79.33 
± 7.13 
9.89 7,19 <.0001 
I 
131.12 
± 19.64 
72.64 ± 
1.78 
87.88 ± 
1.87 
82.35 ± 
16.24 
80.46 ± 
5.83 
105.55 
± 14.28 
120.15 ± 
14.64 
62.91 
± 7.22 
3.97 7,19 0.0077 
dm 
106.32 
± 8.76 
104.08 
± 4.52 
112.95 
± 11.37 
95.43 ± 
3.98 
81.94 ± 
5.53 
97.35 ± 
8.29 
102.61 ± 
5.41 
74.04 
± 6.73 
2.98 7,21 0.0243 
dl 
116.84 
± 6.76 
133.29 
± 3.50 
130.67 
± 3.53 
119.49 ± 
6.69 
103.56 
± 8.01 
122.95 
± 13.94 
158.27 ± 
3.98 
97.93 
± 4.98 
6.94 7,22 0.0002 
vm 
119.15 
± 9.49 
107.30 
± 4.91 
112.16 
± 8.19 
93.85 ± 
5.42 
87.40 ± 
7.69 
105.41 
± 13.97 
101.97 ± 
6.48 
68.27 
± 3.00 
3.98 7,22 0.0059 
vl 99.19 ± 111.91 120.70 100.11 ± 86.38 ± 105.57 110.47 ± 80.32 4.88 7,21 0.0021 
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5.87 ± 3.46 ± 7.04 4.87 6.41 ± 8.81 3.50 ± 6.83 
core 
71.26 ± 
2.49 
71.87 ± 
4.16 
94.06 ± 
2.72 
74.16 ± 
3.95 
67.73 ± 
9.10 
72.90 ± 
3.48 
83.69 ± 
9.61 
62.88 
± 1.51 
3.21 7,20 0.0189 
shell 
82.51 ± 
9.31 
86.76 ± 
7.92 
93.78 ± 
2.14 
72.20 ± 
4.68 
64.91 ± 
12.07 
87.68 ± 
3.85 
90.42 ± 
13.70 
67.65 
± 4.70 
 7,22 ns 
 
PSD-95 
AC 
117.15 
± 3.49 
101.35 
± 2.26 
106.01 
± 1.93 
99.42 ± 
3.82 
121.20 
± 3.16 
105.00 
± 1.62 
121.62 ± 
3.91 
127.65 
± 3.02 
13.87 7,25 <.0001 
M2 
107.05 
± 3.72 
95.57 ± 
3.13 
100.65 
± 2.46 
90.69 ± 
2.60 
110.58 
± 2.51 
95.67 ± 
1.69 
110.03 ±  
0.73 
117.13 
± 2.17 
13.85 7,25 <.0001 
M1 
106.27 
± 3.50 
94.11 ± 
2.03 
102.38 
± 2.67 
92.89 ± 
3.46 
110.45 
± 2.53 
94.15 ± 
1.95 
108.28 ± 
1.71 
115.88 
± 2.18 
12.53 7,25 <.0001 
SS 
101.82 
± 1.93 
90.22 ± 
1.57 
97.38 ± 
1.37 
89.56 ± 
2.90 
107.96 
± 3.23 
90.22 ± 
1.86 
103.96 ± 
4.10 
109.85 
± 2.66 
10.70 7,25 <.0001 
I 
116.18 
± 6.31 
106.23 
± 1.50 
111.79 
± 2.23 
99.78 ± 
3.78 
121.48 
± 4.28 
101.51 
± 1.54 
119.05 ± 
2.22 
129.86 
± 3.29 
11.68 7,25 <.0001 
dm 
105.35 
± 5.04 
94.17 ± 
1.68 
101.94 
± 3.74 
93.52 ± 
2.47 
110.11 
± 4.46 
95.14 ± 
2.01 
104.90 ± 
2.69 
112.77 
± 3.43 
5.79 7,25 0.0005 
dl 
104.23 
± 3.24 
91.95 ± 
1.81 
101.10 
± 4.78 
93.70 ± 
3.17 
113.40 
± 2.89 
95.99 ± 
1.80 
107.00 ± 
4.82 
113.51 
± 3.13 
6.99 7,25 0.0001 
vm 
107.05 
± 6.27 
98.89 ± 
1.88 
106.31 
± 4.38 
95.83 ± 
3.12 
115.65 
± 3.20 
101.29 
± 2.01 
112.93 ± 
4.34 
121.14 
± 3.55 
6.43 7,25 0.0002 
vl 
110.04 
± 3.56 
100.75 
± 2.45 
107.82 
± 3.99 
100.67 ± 
4.13 
122.13 
± 4.11 
102.53 
± 2.61 
115.26 ± 
6.34 
125.65 
± 4.34 
5.98 7,25 0.0004 
core 
111.16 
± 2.81 
100.44 
± 1.72 
109.61 
± 3.41 
98.08 ± 
4.80 
118.16 
± 5.68 
100.76 
± 1.85 
119.63 ± 
5.13 
123.69 
± 5.37 
6.16 7,25 0.0003 
shell 
108.72 
± 4.37 
99.40 ± 
1.74 
110.65 
± 3.07 
97.47 ± 
4.70 
112.39 
± 4.81 
98.91 ± 
2.11 
112.65 ± 
2.41 
121.38 
± 5.33 
5.65 7,25 0.0005 
 
Shank1 
AC 
127.37 
± 5.51 
116.32 
± 3.09 
114.32 
± 1.21 
113.00 ± 
0.69 
116.27 
± 3.84 
113.67 
± 1.11 
111.44 ± 
1.57 
122.23 
± 2.63 
3.57 7,21 0.0109 
M2 
117.92 
± 0.37 
114.03 
± 2.16 
115.17 
± 2.11 
112.71 ± 
1.08 
116.54 
± 3.95 
113.44 
± 1.70 
113.26 ± 
2.17 
122.38 
± 4.06 
 7,20 ns 
M1 
114.27 
± 1.55 
111.67 
± 2.07 
112.32 
± 1.43 
109.69 ± 
0.95 
112.23 
± 3.10 
110.04 
± 1.71 
108.76 ± 
1.44 
117.91 
± 2.64 
 7,20 ns 
SS 
116.60 
± 3.75 
111.55 
± 1.98 
110.93 
± 1.41 
109.09 ± 
1.46 
108.98 
± 2.95 
109.95 
± 2.00 
107.17 ± 
2.12 
114.49 
± 2.52 
 7,20 ns 
I 
125.31 
± 3.03 
118.68 
± 3.56 
115.09 
± 1.29 
111.62 ± 
1.58 
114.12 
± 2.78 
111.64 
± 1.19 
111.99 ± 
2.24 
123.01 
± 2.70 
5.53 7,22 0.0009 
dm 
99.79 ± 
1.25 
102.02 
± 1.66 
99.38 ± 
0.97 
100.22 ± 
0.82 
100.84 
± 0.65 
99.60 ± 
0.95 
94.86 ± 
1.01 
99.89 
± 0.08 
5.10 7,20 0.0019 
dl 
98.27 ± 
1.23 
101.99 
± 1.72 
99.19 ± 
0.66 
97.96 ± 
1.24 
100.06 
± 1.18 
99.43 ± 
0.77 
93.94 ± 
0.53 
98.65 
± 0.23 
5.33 7,21 0.0013 
vm 
101.66 
± 0.66 
104.10 
± 2.26 
100.54 
± 0.99 
100.07 ± 
1.24 
103.26 
±  0.93 
101.56 
±  0.97 
95.96 ±  
1.06 
102.02 
± 0.90 
4.69 7,21 0.0027 
vl 
100.22 
±1.05 
103.23 
±1.86 
100.28 
± 0.85 
99.22 ± 
0.93 
101.45 
± 1.30 
100.53± 
0.96 
95.12 ± 
1.34 
100.80 
± 0.59 
3.74 7,20 0.0094 
core 
104.18 
± 1.22 
106.93 
± 2.12 
100.00 
± 1.13 
98.80 ± 
0.55 
103.19 
± 1.61 
100.58 
± 1.63 
98.04 ± 
0.97 
103.33 
± 1.04 
5.24 7,20 0.0016 
shell 
104.95 
± 0.84 
106.41 
± 1.80 
99.51 ± 
0.74 
101.69 ± 
1.61 
103.06 
± 1.59 
101.98 
± 1.04 
96.29 ± 
1.68 
104.57 
± 0.77 
5.83 7,19 0.0010 
 
Table 2.  
Table 2. The table summarizes values of mRNA expression in relative d.p.m.mean value±S.E.M. for Homer1a, Homer1b, Arc, PSD-95, and Shank1 
transcripts, and significant values (P) and effect sizes (F) along with degrees of freedom of one-way ANOVA. Data are listed by brain regions analyzed. 
AC= anterior cingulated cortex; M2= medial agranular cortex; M1= motor cortex; SS= somatosensory cortex; I = insular cortex; dmCP = dorso-medial 
caudate putamen; dlCP = dorso-lateral caudate putamen; vlCP = ventro-lateral caudate putamen; vmCP = ventro-medial caudate putamen; core = core 
of the nucleus accumbens; shell= shell of the nucleus accumbens. 
Vehicle (NaCl 0.9%, VEH), haloperidol 0.8 mg/kg (HAL0.8), haloperidol 0.5 mg/kg (HAL0.5), haloperidol 0.25 mg/kg (HAL0.25), asenapine 0.3 
mg/kg (ASE0.3), asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05 mg/kg (ASE0.05), olanzapine 2.5 mg/kg (OLA). 
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Figure 5. 
 
Figure 5.Intragroup differences in Homer1a mRNA expression among haloperidol doses (upper panel), i.e. haloperidol 0.8 mg/kg (HAL0.8), 
haloperidol 0.5mg/kg (HAL0.5), and haloperidol 0.25mg/kg (HAL0.25); and among asenapine doses (lower panel), i.e. asenapine 0.3mg/kg (ASE0.3), 
asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05mg/kg (ASE0.05). Data are reported in relative d.p.m. as mean ± S.E.M. * = significant difference at the 
Student-Newman-Keuls (SNK) post-hoc test with Bonferroni correction (p b 0.05). Lines connect groups whose mean mRNA expression is 
significantly different. AC= anterior cingulated cortex; M2= medial agranular cortex; M1= motor cortex; SS= somatosensory cortex; I = insular cortex; 
dmCP = dorso-medial caudate putamen; dlCP = dorso-lateral caudate putamen; vlCP = ventro-lateral caudate putamen; vmCP = ventro-medial caudate 
putamen; core = core of the nucleus accumbens; shell= shell of the nucleus accumbens. 
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 Homer1a Homer1b Arc PSD-95 Shank1 
AC 
 
ASE 0.05 > HAL 0.8 
ASE 0.3 > HAL 0.8 
 
 
 
 
 
ASE0.05>HAL0.25 
ASE0.3>HAL0.25 
ASE0.05>HAL0.8 
ASE0.3>HAL0.8 
ASE0.05>HAL0.5 
ASE0.3>HAL0.5 
 
 
 
M2 
 
ASE 0.05 > HAL 0.8 
ASE 0.3 > HAL 0.8 
ASE 0.1 > HAL 0.8 
ASE 0.05 > HAL 0.25 
 
 
ASE0.05>HAL0.8 
ASE0.05>HAL0.25 
 
 
ASE0.1 > HAL0.8 
 
 
ASE0.3>HAL0.25 
ASE0.3>HAL0.8 
ASE0.05>HAL0.25 
ASE0.05>HAL0.8 
 
 
 
 
M1 
 
ASE 0.05 > HAL 0.8 
ASE 0.05 > HAL0.25 
 
 
ASE0.05>HAL0.8 
ASE0.05>HAL0.25 
 
 
ASE0.05 > HAL0.8 
 
 
ASE0.3>HAL0.25 
ASE0.3>HAL0.8 
ASE0.05>HAL0.25 
ASE0.05>HAL0.8 
 
 
 
 
 
SS  
 
ASE0.05>HAL0.8 
 
 
ASE0.05 > HAL0.8 
 
ASE0.3>HAL0.25 
ASE0.3>HAL0.8 
ASE0.05>HAL0.25 
ASE0.05>HAL0.8 
 
 
 
I 
 
 
 
ASE0.05>HAL0.8 
 
 
 
 
ASE0.3>HAL0.25 
ASE0.05>HAL0.25 
ASE0.3>HAL0.8 
ASE0.05>HAL0.8 
 
 
 
CPdm 
 
HAL0.5>ASE0.1 
 
 
ASE0.05>HAL0.8 
ASE0.3>HAL0.8 
ASE0.05>HAL0.25 
 
 
HAL 0.5>ASE0.3 
 
ASE0.3>HAL0.25 
ASE0.3>HAL0.8 
HAL0.8>ASE0.05 
HAL0.25>ASE0.05 
HAL0.5>ASE0.05 
CPdl 
 
HAL0.5>ASE0.1 
 
 
ASE0.05>HAL0.8 
ASE0.05>HAL0.25 
ASE0.3>HAL0.8 
 
 
 
ASE0.05 > HAL0.25 
HAL0.8 > ASE0.3 
HAL0.5 > ASE0.3 
 
 
ASE0.3>HAL0.8 
ASE0.3>HAL0.25 
ASE0.05>HAL0.8 
 
 
HAL0.8>ASE0.05 
HAL0.5>ASE0.05 
 
CPvm  
 
ASE0.05>HAL0.8 
ASE0.3>HAL0.8 
ASE0.05>HAL0.25 
 
 
 
 
ASE0.3>HAL0.25 
ASE0.05>HAL0.25 
ASE0.3>HAL0.8 
ASE0.05>HAL0.8 
 
 
HAL0.8>ASE0.05 
 
CPvl 
 
HAL0.5>ASE0.1 
HAL0.8>ASE0.1 
HAL0.5>ASE0.3 
HAL0.8>ASE0.3 
 
 
ASE0.05>HAL0.8 
 
 
 
HAL0.5>ASE0.3 
HAL0.8>ASE0.3 
 
 
ASE0.3>HAL0.25 
ASE0.3>HAL0.8 
 
 
HAL0.8>ASE0.05 
HAL0.5>ASE0.05 
 
 
core  
 
ASE0.05>HAL0.8 
 
 
HAL0.5>ASE0.3 
 
 
ASE0.05>HAL0.25 
ASE0.3>HAL0.25 
ASE0.05>HAL0.8 
ASE0.3>HAL0.8 
 
 
HAL0.8>ASE0.05 
HAL0.8>ASE0.1 
 
 
shell      
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HAL0.5>ASE0.1 
HAL0.5>ASE0.3 
ASE0.05>HAL0.8 
HAL0.5>ASE0.1 
ASE0.05>HAL0.25 
 
 
ASE0.05>HAL0.25 HAL0.8>ASE0.05 
 
Table 3. 
 
Table 3. Intergroup differences in genes expression by asenapine vs. haloperidol administration at the Student-Newman-Keuls (SNK) post-hoc test 
with Bonferroni correction (p b 0.05) within each ROI. In bold are reported those significant differences in which at least one of the two groups was 
also significantly different vs. vehicle. ASE0.3= Asenapine 0.3 mg/kg; ASE0.1 = Asenapine 0.1mg/kg; ASE0.05=Asenapine 
0.05mg/kg;HAL0.8=Haloperidol 0.8mg/kg;HAL0.5=Haloperidol 0.5mg/kg;HAL0.25=Haloperidol 0.25 mg/kg. AC=anterior cingulated cortex; 
M2=medial agranular cortex; M1=motor cortex; SS =somatosensory cortex; I=insular cortex; dmCP=dorso-medial caudate putamen; dlCP=dorso-
lateral caudate putamen; vlCP= ventro-lateral caudate putamen; vmCP= ventro-medial caudate putamen; core= core of the nucleus accumbens; shell = 
shell of the nucleus accumbens. 
 
 
 
 Homer1a Homer1b Arc PSD-95 Shank1 
AC   ASE0.1 > OLA OLA>ASE0.1  
M2  OLA>ASE0.1 ASE0.1 > OLA OLA>ASE0.1  
M1 OLA > ASE 0.1  ASE0.05 > OLA OLA>ASE0.1  
SS OLA > ASE 0.1  ASE0.05 > OLA OLA>ASE0.1  
I OLA > ASE 0.1 OLA>ASE0.1 ASE 0.05 > OLA OLA>ASE0.1 
OLA>ASE0.1 
OLA>ASE0.05 
CPdm  OLA>ASE0.1  OLA>ASE0.1 OLA>ASE0.05 
CPdl  OLA>ASE0.1 ASE0.05 > OLA OLA>ASE0.1 OLA>ASE0.05 
CPvm  OLA>ASE0.1 ASE 0.1 > OLA OLA>ASE0.1 OLA>ASE0.05 
CPvl OLA>ASE0.1 OLA>ASE0.1 ASE 0.05 > OLA OLA>ASE0.1 OLA>ASE0.05 
core    OLA>ASE0.1 OLA>ASE0.05 
shell  
OLA>ASE0.1 
OLA>ASE0.3 
 OLA>ASE0.1 OLA>ASE0.05 
 
Table 4. 
 
Table 4. Intergroup differences in gene expression by asenapine vs. olanzapine administration at the Student-Newman-Keuls (SNK) post-hoc testwith 
Bonferroni correction (p b 0.05)within each ROI. In bold are reported those significant differences in which at least one of the two groups was also 
significantly different vs. vehicle. AC=anterior cingulated cortex; M2=medial agranular cortex; M1=motor cortex; SS =somatosensory cortex; I=insular 
cortex; dmCP=dorso-medial caudate putamen; dlCP=dorso-lateral caudate putamen; vlCP= ventro-lateral caudate putamen; vmCP= ventro-medial 
caudate putamen; core= core of the nucleus accumbens; shell = shell of the nucleus accumbens. 
Vehicle (NaCl 0.9%, VEH), haloperidol 0.8 mg/kg (HAL0.8), haloperidol 0.5 mg/kg (HAL0.5), haloperidol 0.25 mg/kg (HAL0.25), asenapine 0.3 
mg/kg (ASE0.3), asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05 mg/kg (ASE0.05), olanzapine 2.5 mg/kg (OLA). 
 
 
 Homer1a Homer1b Arc PSD-95 Shank1 
AC 
 
OLA>HAL0.8 
OLA>HAL0.25 
 
 HAL0.5 > OLA 
OLA>HAL0.25 
OLA>HAL0.8 
OLA>HAL0.5 
 
M2 
OLA>HAL0.8 
OLA>HAL0.25 
OLA>HAL0.5 
OLA>HAL0.8 
OLA>HAL0.25 
 
OLA>HAL0.25 
OLA>HAL0.8 
OLA>HAL0.5 
 
M1 
 
OLA>HAL0.8 
OLA>HAL0.25 
 
OLA>HAL0.8  
OLA>HAL0.25 
OLA>HAL0.8 
OLA>HAL0.5 
 
SS 
 
OLA>HAL0.25 
OLA>HAL0.8 
 
  
OLA>HAL0.25 
OLA>HAL0.8 
OLA>HAL0.5 
 
I  OLA>HAL0.8  OLA>HAL0.25 OLA>HAL0.25 
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OLA>HAL0.8 
 
OLA>HAL0.8 
OLA>HAL0.5 
CPdm  
OLA>HAL0.8 
OLA>HAL0.25 
 
HAL0.5>OLA 
OLA>HAL0.25 
OLA>HAL0.8 
 
 
CPdl  
OLA>HAL0.8 
OLA>HAL0.25 
HAL0.8 > OLA 
HAL0.5 > OLA 
OLA>HAL0.8 
OLA>HAL0.25 
 
CPvm  
OLA>HAL0.8 
OLA>HAL0.25 
HAL0.5>OLA 
HAL0.8>OLA 
OLA>HAL0.25 
OLA>HAL0.8 
OLA>HAL0.5 
 
 
CPvl  
OLA>HAL0.8 
OLA>HAL0.25 
HAL0.5>OLA 
HAL0.8>OLA 
 
OLA>HAL0.8 
OLA>HAL0.25 
OLA>HAL0.5 
 
 
core   HAL0.5>OLA 
OLA>HAL0.25 
OLA>HAL0.8 
 
 
shell  
OLA>HAL0.8 
OLA>HAL0.25 
 
 
OLA>HAL0.25 
OLA>HAL0.8 
 
 
 
 
Table 5. 
 
Table 5. Intergroup differences in genes expression by haloperidol vs. olanzapine administration at the Student-Newman-Keuls (SNK) post-hoc test 
with Bonferroni correction (p b 0.05) within each ROI. In bold are reported those significant differences in which at least one of the two groups was 
also significantly different vs. vehicle. AC=anterior cingulated cortex; M2=medial agranular cortex; M1=motor cortex; SS =somatosensory cortex; 
I=insular cortex; dmCP=dorso-medial caudate putamen; dlCP=dorso-lateral caudate putamen; vlCP= ventro-lateral caudate putamen; vmCP= ventro-
medial caudate putamen; core= core of the nucleus accumbens; shell = shell of the nucleus accumbens. 
Vehicle (NaCl 0.9%, VEH), haloperidol 0.8 mg/kg (HAL0.8), haloperidol 0.5 mg/kg (HAL0.5), haloperidol 0.25 mg/kg (HAL0.25), asenapine 0.3 
mg/kg (ASE0.3), asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05 mg/kg (ASE0.05), olanzapine 2.5 mg/kg (OLA). 
 
 
 
 
2.2.Homer1b 
2.2.1. Gene expression differences between antipsychotic-administered groups and control 
group. 
Homer1b expression was significantly decreased mostly by HAL0.8 in few cortical and striatal 
regions. ASE0.05 and olanzapine significantly increased gene expression levels limitedly to the shell 
of the nucleus accumbens (Figure 4., Table 2.).  
 
2.2.2. Haloperidol intragroup gene expression differences. 
Homer1b expression was poorly affected by the different doses of haloperidol considered in this 
study (Figure 6.). The major differences were found between HAL0.5 and HAL0.8, with the first 
treatment significantly increasing Homer1b mRNA compared to the latter treatment in cortical and 
striatal regions. 
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Figure 6. 
 
Figure 6. Intragroup  differences in Homer1bmRNA expression among haloperidol doses (upper panel), i.e. haloperidol 0.8mg/kg (HAL0.8), 
haloperidol 0.5mg/kg (HAL0.5), and haloperidol 0.25mg/kg (HAL0.25); and among asenapine doses (lower panel), i.e. asenapine 0.3mg/kg (ASE0.3), 
asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05mg/kg (ASE0.05). Data are reported in relative d.p.m. as mean ± S.E.M. * = significant difference at the 
Student-Newman-Keuls (SNK) post-hoc test with Bonferroni correction (p b 0.05). Lines connect groups whose mean mRNA expression is 
significantly different. AC=anterior cingulated cortex; M2=medial agranular cortex; M1=motor cortex; SS =somatosensory cortex; I=insular cortex; 
dmCP=dorso-medial caudate putamen; dlCP=dorso-lateral caudate putamen; vlCP= ventro-lateral caudate putamen; vmCP= ventro-medial caudate 
putamen; core= core of the nucleus accumbens; shell = shell of the nucleus accumbens. 
 
 
2.2.3. Asenapine intragroup gene expression differences.   
The different doses of asenapine administered affected Homer1b in both cortical and striatal regions 
(Figure 6.). Specifically, the low dose of asenapine significantly increased gene expression levels 
compared mostly to ASE0.1 administration in the ROIs considered.  
2.2.4. Asenapine vs. Haloperidol gene expression differences. 
In the ASE0.05 treated group, Homer1b mRNA levels in the cortex and in the striatum were 
significantly higher mainly compared to HAL0.8 and HAL0.25 (Table 3.). In the striatum, also 
ASE0.3 showed to significantly trigger gene expression at a higher extent compared to HAL0.8, 
while HAL0.5 increased Homer1b compared to ASE0.1 only in the shell of the nucleus accumbens 
(Table 3.). 
 
2.2.5. Asenapine vs. Olanzapine gene expression differences.  
Homer1b mRNA were significantly increased by olanzapine compared to ASE0.1 in both cortex and  
striatum regions (Table 4.).  
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2.2.6. Haloperidol vs. Olanzapine gene expression differences.  
Olanzapine induced Homer1b gene levels in both cortical and striatal regions at a higher extent 
compared to HAL0.8 and HAL0.25 (Table 5.).  
 
2.3. Relative Ratio of Homer1a/Homer1b expression 
2.3.1.Haloperidol treatments 
In the cortex, HAL0.8 administration significantly shifted the ratio toward Homer1b in ACC, MAC, 
MC and IC, HAL0.5 significantly shifted the ratio toward Homer1b in only one cortical region, 
while HAL0.25 chronic administration did not impact the isoforms relative ratio (Figure 7.). 
In the striatum, HAL0.8 shifted the ratio significantly toward Homer1a in the ventral caudate 
putamen, in the dorsolateral caudate putamen and in the nucleus accumbens. HAL0.25 and HAL0.5 
were found to shift the ratio significantly toward Homer1a expression in the dorsal and ventro-lateral 
caudate putamen, and HAL0.5 administration produced the same effect also in the nucleus 
accumbens. (Figure 7.) 
 
2.3.2. Asenapine treatments 
In the IC region of the cortex, the administration of all the three doses of asenapine significantly 
shifted the ratio toward Homer1b expression (Figure 7.). ASE0.1 and ASE0.3 treatments produced 
the same effect also in MC, while only ASE0.1 shifted the ratio toward Homer1b in the SS region. 
In the striatum, the ratio toward Homer1a expression was shifted in the dorsolateral caudate putamen 
by all the three doses of asenapine (Figure 7.). ASE0.05 and AS0.3 administration produced the 
same effect also in the dorso-medial and in the ventro-lateral caudate putamen, respectively. Finally, 
ASE0.1 and ASE0.3 shifted the ratio significantly toward Homer1a in the shell of the nucleus 
accumbens (Figure 7.) 
 
2.3.3. Olanzapine treatment 
In the cortex, olanzapine administration did not impact the relative ratio of Homer1a/Homer1b 
(Figure 7.) 
In the striatum, olanzapine shifted the relative ratio significantly toward Homer1a in the lateral 
caudate putamen and in the nucleus accumbens (Figure 7.). 
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Figure 7. 
Figure 7. Homer1a/Homer1b ratio by haloperidol 0.8mg/kg (HAL0.8), haloperidol 0.5mg/kg (HAL0.5), haloperidol 0.25mg/kg (HAL0.25), asenapine 
0.3mg/kg (ASE0.3), asenapine0.1mg/kg (ASE0.1), asenapine 0.05 mg/kg (ASE0.05), olanzapine 2.5 mg/kg (OLA)within each ROI; *=significant 
difference at the Student's t-test (p b 0.05). AC=anterior cingulated cortex;M2= medial agranular cortex; M1= motor cortex; SS = somatosensory 
cortex; I= insular cortex; dmCP= dorso-medial caudate putamen; dlCP= dorso-lateral caudate putamen; vlCP= vventro-lateral caudate putamen; 
vmCP= ventro-medial caudate putamen; core= core of the nucleus accumbens; shell = shell of the nucleus accumbens. 
 
 
2.4.Arc 
2.4.1. Gene expression differences between antipsychotic-administered groups and control 
group. 
In the cortex,  Arc expression levels were significantly reduced by all haloperidol doses. Also  
ASE0.1 and ASE0.3 and olanzapine exerted the same effects on the transcript levels of expression 
(Figure 4., Table 2.). 
In the striatum, Arc mRNA levels were mostly reduced by olanzapine administration (Figure 4., 
Table 2.).  
 
2.4.2. Haloperidol intragroup gene expression differences. 
 The comparison among the different doses of haloperidol did not produce many significant Arc 
expression differences (Figure 8.). The major differences were found in the shell of the nucleus 
accumbens, where HAL0.5 triggered significantly higher expression of Arc compared to HAL0.8 
(Figure 8.). 
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2.4.3. Asenapine intragroup gene expression differences.   
The main differences in Arc expression were observed in the dorso-lateral caudate putamen, where 
the transcript was significantly induced at a higher extent by ASE0.05 compared to ASE0.3 and 
ASE0.1 only (Figure 8.).  
 
 
Figure 8. 
Figure 8. Intragroup differences in Arc mRNA expression among haloperidol doses (upper panel), i.e. haloperidol 0.8 mg/kg (HAL0.8), haloperidol 0.5 
mg/kg (HAL0.5), and haloperidol 0.25 mg/kg (HAL0.25); and among asenapine doses (lower panel), i.e. asenapine 0.3 mg/kg (ASE0.3), asenapine 0.1 
mg/kg (ASE0.1), asenapine 0.05 mg/kg (ASE0.05). Data are reported in relative d.p.m. as mean ± S.E.M. * = significant difference at the Student-
Newman-Keuls (SNK) post-hoc test with Bonferroni correction (p b 0.05). Lines connect groups whose mean mRNA expression is significantly 
different 
 
 
2.4.4. Asenapine vs. Haloperidol gene expression differences. 
In the cortex, Arc expression was found significantly higher in the ASE0.05 and ASE0.1 treated 
groups compared to HAL0.8 (Table 3).  
In the majority of the striatal regions considered, Arc mRNA levels were found significantly higher 
in the HAL0.5 and HAL0.8 treated groups compared to ASE0.3 treated group (Table 3.). To note, 
only in the dorso-lateral caudate putamen ASE0.05 induced higher levels of the transcript compared 
to the low dose of haloperidol (Table 3.). 
 
2.4.5. Asenapine vs. Olanzapine gene expression differences.  
In both cortical and striatal regions, ASE0.05 and ASE0.1 induced significantly higher levels of Arc 
mRNA when compared to olanzapine treated group (Table 4.).  
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2.4.6. Haloperidol vs. Olanzapine gene expression differences.  
The main significant differences in gene expression were found in the striatum, where haloperidol 
induced Arc mRNA levels at a higher extent compared to olanzapine (Table 5.)  
 
 2.5.PSD-95 
2.5.1. Gene expression differences between antipsychotic-administered groups and control 
group. 
In cortical regions, PSD-95 expression was significantly decreased by HAL0.8, HAL0.25 and by 
ASE0.1 (Figure 4., Table 2.).  
In the striatum, gene expression levels were not affected by the antipsychotics chronically 
administered in this study when compared to the control group (Figure 4., Table 2.).  
 
2.5.2. Haloperidol intragroup gene expression differences. 
The different doses of haloperidol did not affect PSD-95 expression levels differentially in the 
cortical and striatal regions considered herein (Figure 9.).  
 
2.5.3. Asenapine intragroup gene expression differences.   
In both cortical  and striatal regions, PSD-95 expression was affected mainly by ASE0.05 and 
ASE0.3  that significantly increased gene expression compared to ASE0.1 (Figure 9.).  
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Figure 9. 
Figure 9. Intragroup differences in PSD-95 mRNA expression among haloperidol doses (upper panel), i.e. haloperidol 0.8 mg/kg (HAL0.8), 
haloperidol 0.5 mg/kg (HAL0.5), and haloperidol 0.25mg/kg (HAL0.25); and among asenapine doses (lower panel), i.e. asenapine 0.3mg/kg (ASE0.3), 
asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05mg/kg (ASE0.05). Data are reported in relative d.p.m. as mean ± S.E.M. * = significant difference at the 
Student-Newman-Keuls (SNK) post-hoc test with Bonferroni correction (p b 0.05). Lines connect groups whose mean mRNA expression is 
significantly different. 
 
2.5.4. Asenapine vs. Haloperidol gene expression differences. 
In cortical ROIs, PSD-95 transcript was found significantly higher mainly in the ASE0.05 and 
ASE0.3 treated groups compared to all haloperidol treated groups (Table 3.).  
In the majority of the striatal regions, ASE0.05 and ASE0.3 increased gene expression mainly 
compared to the HAL0.25 and HAL0.8 (Table 3.). 
 
2.5.5. Asenapine vs. Olanzapine gene expression differences.  
In both cortex and striatum, olanzapine was found to significantly increase PSD-95 expression 
compared to ASE0.1 (Table 4.).  
 
2.5.6. Haloperidol vs. Olanzapine gene expression differences.  
In the cortex, olanzapine significantly induced higher levels of PSD-95 mRNA compared to all doses 
of haloperidol administered. 
In the striatum, olanzapine was found to significantly induce the transcript when compared to 
HAL0.8 and HAL0.25 (Table 5.).  
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2.6. Shank1 
2.6.1. Gene expression differences between antipsychotic-administered groups and control 
group. 
In the cortex, Shank1 mRNA levels were found decreased only in the ACC and IC regions by 
HAL0.25, HAL0.5, ASE0.05 and ASE0.1 (Figure 4., Table 2.).  
In the striatum, ASE0.05 significantly decreased Shank1 transcript levels in all the regions 
considered herein (Figure 4., Table 2.).  
 
2.6.2. Haloperidol intragroup gene expression differences. 
Shank1 mRNA expression was found affected only in the striatum. Particularly, HAL0.8 increased 
significantly the gene expression compared to the intermediate and low dose of haloperidol 
considered herein in the nucleus accumbens (Figure 10.). 
  
2.6.3. Asenapine intragroup gene expression differences.   
As observed within the haloperidol treated groups, Shank1 mRNA expression was found affected 
only in the striatum by the different doses of asenapine considered in this study (Figure 9). Indeed, 
the ASE0.05 significantly decreased gene expression compared to ASE0.1 and ASE0.3 in almost all 
caudate putamen regions and in the shell of the nucleus accumbens (Figure 10.).  
 
 
Figure 10. 
 
Figure 10. Intragroup differences in Shank1 mRNA expression among haloperidol doses (upper panel), i.e. haloperidol 0.8 mg/kg (HAL0.8), 
haloperidol 0.5 mg/kg (HAL0.5), and haloperidol 0.25mg/kg (HAL0.25); and among asenapine doses (lower panel), i.e. asenapine 0.3mg/kg (ASE0.3), 
asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05mg/kg (ASE0.05). Data are reported in relative d.p.m. as mean ± S.E.M. * = significant difference at the 
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Student-Newman-Keuls (SNK) post-hoc test with Bonferroni correction (p b 0.05). Lines connect groups whose mean mRNA expression is 
significantly different. 
 
 
2.6.4. Asenapine vs. Haloperidol gene expression differences. 
In the striatum, Shank1 mRNA levels were significantly lower in the ASE0.05 treated group when 
compared to HAL0.8 and HAL0.5 treated groups (Table 3.). 
 
2.6.5. Asenapine vs. Olanzapine gene expression differences.  
In both cortical and striatal regions, Shank1 mRNA levels were found significantly increased by 
olanzapine when compared to ASE0.05 (Table 4.).  
 
2.6.6.Haloperidol vs. Olanzapine gene expression differences.  
Olanzapine triggered Shank1 expression at a significant higher extent compared to HAL0.25 only in 
the IC region of the cortex (Table 5.).  
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CHAPTER 5  
 
Quantitative comparison of acute versus chronic antipsychotic treatments on the immediate 
early gene Homer1a expression profile 
 
1.Rationale 
 
Molecular effects of antipsychotics may dramatically change according to the timing of 
administration (de Bartolomeis et al., 2015). Antipsychotic agents significantly modulate the 
expression and topography of PSD transcripts after acute treatments in animal studies (de 
Bartolomeis et al., 2013b; Fumagalli et al., 2008). Indeed, in a previous acute paradigm of 
administration, increasing doses of haloperidol, olanzapine and asenapine have been reported to 
induce a progressive recruitment of cortical/sub-cortical regions in rat brains(de Bartolomeis et al., 
2015). Specifically, the administration of the above mentioned compounds at each 
dose produced a significant increase in the expression of early and constitutive genes  in cortical and 
sub-cortical ROIs, with the exception of Arc mRNA expression in the cortex (de Bartolomeis et al., 
2015). 
Following the observations made in the previous chapter, we therefore aimed at investigating the 
molecular effects of acute versus chronic administration of the same compounds (haloperidol, 
olanzapine and asenapine) at different doses, in order to obtain an head-to-head comparison of the 
two paradigms of treatment on the expression pattern of the IEG Homer1a. Indeed, our goal was to 
use Homer1a expression as a molecular tool to assess putative plastic PSD rearrangements after 
acute treatments versus chronic ones.  
To do so, we co-exposed slides corresponding to the treatment groups of both acute and chronic 
paradigms (namely: VEH; HAL0.25; HAL0.5; HAL0.8; ASE0.05; ASE0.1; ASE0.3; OLA) on the 
same auto-radiographic sheet. Mean values obtained by quantitation of the signal intensity for each 
treatment were normalized by subdividing them with vehicle’s mean values obtained in the 
corresponding ROI. Therefore, results were given as a percentage of vehicle mRNA expression. 
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The Student's t-test was used to compare acute versus chronic normalized Homer1a  mRNA levels 
by each antipsychotic in each ROI. In all tests, significance was set at p<0.05. The statistical analyses 
were performed using JMP9.0.1 software. 
 
2.Results 
 
The main result obtained by this comparison was that Homer1a expression resulted significantly 
lower in chronic paradigms of treatment compared to acute ones. These observations were reported 
comparing the same compound and the same dose administered acutely or chronically. Finally, the 
pattern of expression of the IEG tested was affected both in cortical and sub-cortical ROIs, 
particularly depending on the compound tested (Table 6.). 
 
2.1 Haloperidol induced Homer1a gene expression 
The comparison of acute versus chronic haloperidol administration on Homer1a mRNA transcript 
resulted in significantly higher expression levels of the gene in the acute treated group of animals 
with respect to the chronically treated ones in striatal ROIs (Figure 11.). Moreover, the HAL0.8  
group showed significant differences in gene expression also in the MC, SS and IC regions of the 
cortex. 
 
2.2 Asenapine induced Homer1a gene expression 
The comparison of acute versus chronic asenapine administration on Homer1a mRNA transcript 
resulted in significantly higher expression levels of the gene in the acute treated group of animals in 
respect of the chronically treated ones in several cortical and striatal ROIs (Figure 12.). Moreover,  
with increasing doses of the compound, the expression of the gene become significantly different in 
more striatal regions. 
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2.3 Olanzapine induced Homer1a gene expression 
The comparison of acute versus chronic olanzapine administration on Homer1a mRNA transcript 
resulted in significantly higher expression levels of the gene in the acute treated group of animals in 
respect of the chronically treated ones in several cortical and striatal ROIs (Figure 13.). 
 
 
 
Figure 11. 
Figure 11. Normalized Homer1a mRNA levels after acute (blue bars)  versus chronic (orange bars) haloperidol administration at different doses. Data 
are given as a percentage vehicle mRNA expression. * significant difference at the Student’s t test (p<.05). 
Haloperidol 0.8 mg/kg (HAL0.8), haloperidol 0.5 mg/kg (HAL0.5), and haloperidol 0.25mg/kg (HAL0.25).   
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Figure 12. 
Figure 12. Normalized Homer1a mRNA levels after acute (blue bars)  versus chronic (orange bars) asenapine  administration at different doses. Data 
are given as a percentage vehicle mRNA expression. * significant difference at the Student’s t test (p<.05). 
Asenapine 0.3mg/kg (ASE0.3), asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05mg/kg (ASE0.05). 
 
 
Figure 13. 
Figure 13. Normalized Homer1a mRNA levels after acute (blue bars)  versus chronic (orange bars) olanzapine  administration. Data are given as a 
percentage vehicle mRNA expression. * significant difference at the Student’s t test (p<.05). 
Olanzapine (OLA). 
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Treatment ROI Student’s t   
p df F 
OLA ACC >.05 1,4 0,0168  
MAC >.05 1,4 0,3945  
MC >.05 1,4 2,9746  
SS >.05 1,4 0,2723  
I .0497 1,4 7,7406 Acute>Chronic 
CP-DM >.05 1,4 4,3766  
CP-DL .0147 1,4 16,9410 Acute>Chronic 
CP-VL >.05 1,4 6,0657  
CP-VM .0033 1,4 39,4520 Acute>Chronic 
CAb .0327 1,4 10,2759 Acute>Chronic 
SAb >.05 1,4 6,8605  
ASE 0.05 ACC >.05 1,6 0,2336  
MAC >.05 1,6 0,7224  
MC >.05 1,6 3,0382  
SS .0337 1,6 7,5119 Acute>Chronic 
I >.05 1,6 4,7885  
CP-DM .0238 1,6 9,0373 Acute>Chronic 
CP-DL .0111 1,6 13,0899 Acute>Chronic 
CP-VL >.05 1,6 2,8961  
CP-VM .0026 1,6 24,3438 Acute>Chronic 
CAb >.05 1,6 5,3797  
SAb >.05 1,6 2,2209  
ASE 0.1 ACC >.05 1,6 0,7625  
MAC >.05 1,6 1,9828  
MC >.05 1,6 4,4781  
SS >.05 1,6 3,3458  
I >.05 1,6 4,7971  
CP-DM .0284 1,6 8,2339 Acute>Chronic 
CP-DL .0181 1,6 10,3792 Acute>Chronic 
CP-VL >.05 1,6 5,4368  
CP-VM .0340 1,6 7,4771 Acute>Chronic 
CAb .0452 1,6 6,3562 Acute>Chronic 
SAb >.05 1,6 1,3358  
ASE 0.3 ACC >.05 1,5 0,0839  
MAC >.05 1,5 0,1139  
MC >.05 1,5 1,7002  
SS >.05 1,5 2,0861  
I .0188 1,5 11,7140 Acute>Chronic 
CP-DM >.05 1,5 3,9544  
CP-DL .0024 1,5 32,1173 Acute>Chronic 
CP-VL .0093 1,5 16,8715 Acute>Chronic 
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CP-VM .0216 1,5 10,8585 Acute>Chronic 
CAb .0422 1,5 7,3534 Acute>Chronic 
SAb >.05 1,5 2,4902  
HAL 0.25 ACC >.05 1,6 1,2759  
MAC >.05 1,6 1,2917  
MC >.05 1,6 1,9612  
SS >.05 1,6 0,2658  
I >.05 1,6 1,7308  
CP-DM .0258 1,6 8,6707 Acute>Chronic 
CP-DL .0012 1,6 33,4286 Acute>Chronic 
CP-VL .0037 1,6 21,0306 Acute>Chronic 
CP-VM .0046 1,6 19,3126 Acute>Chronic 
CAb .0058 1,6 17,4517 Acute>Chronic 
SAb >.05 1,6 0,6564  
HAL 0.5 ACC >.05 1,5 0,0363  
MAC >.05 1,5 3,4733  
MC >.05 1,5 5,0683  
SS >.05 1,5 0,7583  
I >.05 1,5 3,1577  
CP-DM .0013 1,5 41,9684 Acute>Chronic 
CP-DL .0086 1,5 17,4832 Acute>Chronic 
CP-VL .0008 1,5 51,2822 Acute>Chronic 
CP-VM .0040 1,5 25,3290 Acute>Chronic 
CAb .0025 1,5 31,4600 Acute>Chronic 
SAb .0048 1.5 23,1624 Acute>Chronic 
HAL 0.8 ACC >.05 1,6 0,4230  
MAC >.05 1,6 2,0622  
MC .0135 1,6 11,9538 Acute>Chronic 
SS .0207 1,6 9,7079 Acute>Chronic 
I .0007 1,6 40,9548 Acute>Chronic 
CP-DM .0124 1,6 12,4444 Acute>Chronic 
CP-DL .0062 1,6 17,0013 Acute>Chronic 
CP-VL .0253 1,6 8,7540 Acute>Chronic 
CP-VM .0007 1,6 40,5462 Acute>Chronic 
CAb .0039 1,6 20,6230 Acute>Chronic 
SAb .0014 1,6 31,6224 Acute>Chronic 
 
Table 6. 
Table 6. The table summarizes the P values and effect sizes (F) along with degrees of freedom of Student’s t test.   Data are listed by brain regions 
analyzed for each treatment. Haloperidol 0.8 mg/kg (HAL0.8), haloperidol 0.5 mg/kg (HAL0.5), and haloperidol 0.25mg/kg (HAL0.25);  asenapine 
0.3mg/kg (ASE0.3), asenapine 0.1 mg/kg (ASE0.1), asenapine 0.05mg/kg (ASE0.05); olanzapine (OLA). 
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CHAPTER 6 
 
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density 
transcripts expression. 
 
1.Rationale 
 
In clinical practice, antipsychotic therapy may be complicated by the exposure to substances such as 
caffeine and nicotine, which are among the most used ones by schizophrenia patients (Thoma and 
Daum, 2013). Intriguingly, these abuse-conducts may be functional for schizophrenia patients to 
alleviate antipsychotic side effects and/or psychotic symptoms (Acuna-Lizama et al., 2013; 
Featherstone and Siegel, 2015; Iasevoli et al., 2013a; Misiak et al., 2015). Indeed, caffeine and 
nicotine may counteract extrapyramidal side effects of antipsychotics (Oertel and Schulz, 2016) and 
both adenosine receptors (which are directly modulated by caffeine) and nicotine receptors 
modulation has been considered a potential pharmacological strategy  to address residual symptoms 
not responding or responding poorly to conventional antipsychotics (Marcus et al., 2016; Rial et al., 
2014). On the contrary, several studies have demonstrated that tobacco smoking and caffeine intake 
may impair neurocognitive outcomes, negative symptoms and social performances in schizophrenia 
patients (Iasevoli et al., 2013a; Nunez et al., 2015). Therefore, the final effect of caffeine or nicotine 
assumption in schizophrenia patients is still matter of debate. 
Caffeine exerts an antagonist action on adenosine A1 receptor and A2A receptor (Chen et al., 2001), 
with the latter forming heteromers with postsynaptic D2 receptors in striatum (Ferre, 2016) . This 
observation can be of particular value, since the antagonistic action of caffeine on A2A receptors 
may modulate D2 receptors-mediated neurotransmission and therefore modify antipsychotics 
molecular action. For what concerns nicotine, it acts as an agonist at nicotinic acetylcholine (nACh) 
receptors, and this binding affinity particularly on receptors located on midbrain dopamine and 
GABAergic neurons has a final effect on dopamine firing  (Dani and Bertrand, 2007; Pidoplichko et 
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al., 1997). To date, little is known about the molecular changes induced on brain plasticity processes 
by these compounds when given in association to antipsychotics. Considering the translational value 
of the research, we aimed at evaluating whether and to what extent PSD gene expression 
(Oligodeoxyribonucleotides complementary to bases sequence of Homer1a, Homer1b and Arc genes 
mRNAs are listed in Table 7.) and protein levels were affected by acute systemic administration of 
caffeine or nicotine alone or in association with the prototype first generation antipsychotic 
haloperidol or the indirect dopamine agonist GBR-12909.  
Finally, behavioral (i.e. open field locomotor activity) testing was also carried out.  
Rats were randomly assigned to one of the following treatment groups (n=8 for each group): 1) the 
control group receiving vehicle + vehicle injections (VEH); 2) vehicle + haloperidol 0.8 mg/kg 
(HAL); 3) vehicle + GBR-12909 30 mg/kg (GBR); 4) vehicle + caffeine 40 mg/kg (CAF); 5) vehicle 
+ nicotine 1.5 mg/kg (NIC); 6) caffeine 40 mg/kg + haloperidol 0.8 mg/kg (CAF+HAL); 7) nicotine 
1.5 mg/kg + haloperidol 0.8 mg/kg (NIC+HAL). The two subsequent injections were spaced by 20 
minutes and were performed i.p.. All drugs were given at behaviorally active doses and caffeine and 
nicotine were administered at doses  mimicking an intermediate-to-high caffeine/nicotine intake in 
humans (Cohen and George, 2013; Iasevoli et al., 2010b; Pechlivanova et al., 2010). Locomotor 
activity monitoring was assessed 20 minutes after the last injection.  
For in situ hybridization histochemistry, animals were killed 90 minutes after the last injection. 
For western blotting analysis, killing was performed 150 minutes after the last injection.  
One-Way ANOVAs were used to compare groups and analyze treatment effects. The SNK  post-hoc 
test with the Bonferroni correction was used to determine the locus of effects for significant ANOVA 
results. In all tests, significance was set at p<0.05. The statistical analyses were performed using 
JMP9.0.1 software. 
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Probe cDNA length (bp) cDNA position mRNA Gen-Bank# 
Homer1a 48 2527–2574 Homer1a U92079 
Homer1b/c 48 1306–1353 Homer1b/c AF093268 
Arc 45 789-833 Arc NM019361 
Table 7. 
Table 7. Probes for in situ hybridization histochemistry. 
 
2.Results 
 
The  major findings of the present study was that caffeine and nicotine per se were found to exert 
minor molecular effects on PSD molecules implicated in synaptic plasticity and antipsychotic 
induced molecular adaptations. However, these substances strongly affected haloperidol-mediated 
effects on Homer1a and Arc transcripts and, on the behavioral level, the locomotor activity appeared 
significantly different in groups receiving those substances plus haloperidol compared to the control 
group.  
Results are listed as gene expression results obtained for each gene taken into account, followed by 
protein levels analyses at the level of the striatum. Finally, locomotor activity results are provided. 
 
2.1.Gene Expression Analyses 
2.1.1.Homer1a 
In the cortex, only in the ACC region Homer1a expression was significantly reduced by caffeine plus 
haloperidol as compared to vehicle as well as to haloperidol alone.  
In the striatum, Homer1a mRNA was significantly increased by HAL in all caudate putamen and 
nucleus accumbens regions compared to the control group. Nicotine alone only induced a significant 
Homer1a gene expression in the core of the nucleus accumbens, but the combination of NIC+HAL 
strongly enhanced Homer1a expression in dorso-medial and dorso-lateral striatum and in the nucleus 
accumbens. Caffeine administration alone  provoked scarce modifications in striatal Homer1a 
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expression, while CAF+HAL  provoked a peculiar decrease in the signal of the gene in medial 
caudate putamen and in the nucleus accumbens core as compared to VEH. 
GBR-12909 induced Homer1a mRNA expression in ventro-maedial caudate putamen and in the 
shell of the nucleus accumbens.  
All statistically significant results are detailed in Table 8. Significant differences as compared to 
vehicle are depicted in Figure 14, intergroup differences are graphed in Figure 15.   
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Figure 14. 
 
Figure 14. Exemplificative autoradiographic film images of Homer1a, Arc, Homer1b mRNA expression detected by means of in situ hybridization 
histochemistry in coronal brain sections after acute treatment by vehicle+vehicle (NaCl 0.9%, VEH); vehicle+haloperidol 0.8mg/kg (HAL); 
vehicle+GBR-12909 30mg/kg (GBR); vehicle+caffeine 40mg/kg (CAF); vehicle+nicotine 1.5mg/kg (NIC); caffeine 40mg/kg+haloperidol 0.8mg/kg 
(CAF+HAL); nicotine 1.5mg/kg+haloperidol 0.8mg/kg (NIC+HAL). In the row below each gene-related series of exemplificative autoradiogram 
images, diagrams of regions of interest (ROIs) in which gene expression was measured were depicted. ROI-delimited color marks depict significant 
changes of mRNA expression compared to controls (i.e. VEH-treated rats) at the Student-Newman-Keuls post-hoc test (ANOVA, p<0.05). Dark red: 
significant increase (p<0.001); light red: significant increase (p<0.05); dark blue: significant decrease (p<0.001); light blue: significant decrease 
(p<0.05); no color mark: no significant differences. AC=anterior cingulated cortex; M2=medial agranular cortex; M1=motor cortex; SS=somatosensory 
cortex; I=insular cortex; dm=dorso-medial caudate putamen; dl=dorso-lateral caudate putamen; vl= ventro-lateral caudate putamen; vm=ventro-medial 
caudate putamen; core=core of the nucleus accumbens; shell=shell of the nucleus accumbens. Modified from Paxinos and Watson (Paxinos and Watson, 
1997) 
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 ANOVA Post-hoc Test 
 F(df) p Student-Newman-Keuls Bonferroni 
ACC 2.79 6,17 0.04 
CAF+HAL < VEH p=0.002 
 
CAF+HAL < HAL p=0.006 
CAF+HAL < VEH p=0.01 
 
CAF+HAL < HAL p=0.04 
MAC  ns   
MC  ns   
SS  ns   
IC  ns   
CP-DM 11.86 6,17 <0.0001 
HAL > VEH p=0.0004 
CAF+HAL < VEH p=0.03 
NIC+HAL > VEH  p=0.03 
 
CAF < GBR p=0.01 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p=0.0008 
NIC+HAL < HAL p=0.04 
HAL > VEH p=0.002 
 
 
 
 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC<HAL p=0.005 
 
CP-DL 6.38 6,17 0.001 
HAL > VEH p=0.0004 
 
CAF < HAL p<0.0001 
CAF+HAL < HAL p=0.001 
NIC < HAL p=0.0002 
NIC+HAL > VEH  p=0.005 
HAL > VEH p=0.002 
 
CAF < HAL p<0.0001 
NIC < HAL p=0.001 
CAF+HAL < HAL p=0.007 
NIC+HAL > VEH  p=0.03 
CP-VM 16.09 6,17 <0.0001 
HAL > VEH p=0.001 
GBR > VEH p=0.03 
CAF+HAL < VEH p=0.01 
 
CAF < GBR p=0.0003 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p<0.0001         
NIC+HAL < HAL p=0.001 
HAL > VEH p=0.007 
 
 
 
CAF < GBR p=0.002 
CAF+HAL < HAL p<0.0001         
CAF < HAL p<0.0001 
NIC < HAL p<0.0001         
NIC+HAL < HAL p=0.007 
CP-VL 10.55 6,17 <0.0001 
HAL > VEH p<0.0001 
 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p<0.0001         
NIC+HAL < HAL p=0.0004 
HAL > VEH p<0.0001 
 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p<0.0001         
NIC+HAL < HAL p=0.003 
CAb 22.26 6,18 <0.0001 
HAL > VEH p<0.0001 
CAF+HAL < VEH p=0.03 
NIC+HAL > VEH p=0.02 
 
CAF < GBR p=0.001 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p<0.0001         
NIC+HAL < HAL p=0.0001 
HAL > VEH p<0.0001 
 
 
 
CAF < GBR p=0.007 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p<0.0001         
NIC+HAL < HAL p=0.001 
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SAb 10.32 6,18 <0.0001 
HAL > VEH p<0.0001 
GBR > VEH p=0.009 
NIC > VEH p=0.05 
NIC+HAL > VEH p=0.0005 
 
CAF < GBR p=0.01 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p=0.008        
NIC+HAL < HAL p=0.03 
HAL > VEH p<0.0001 
GBR > VEH p=0.05 
 
NIC+HAL > VEH p=0.003 
 
 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001         
NIC < HAL p=0.05        
 
 
Table 8. 
 
Table 8. Summarization of statistical data for Homer1a mRNA expression analysis. In this table, we provided statistical data outputs after 
quantification of relativized signal intensity of Homer1a mRNA expression in ISHH. Da Data have been listed for Regions of Interest as effect size (F), 
degrees of freedom (df), and two-tailed p level. In case of significant ANOVA, results of group pair’s comparisons at the Student-Newman-Keuls post-
hoc test have been reported. Despite being an over-conservative test, we also included results after Bonferroni’s correction. Only significant differences 
surviving after correction were reported. Significant differences vs. vehicle have been given in italics, for clarity. 
Vehicle+vehicle (NaCl 0.9%, VEH); vehicle+haloperidol 0.8mg/kg (HAL); vehicle+GBR-12909 30mg/kg (GBR); vehicle+caffeine 40mg/kg (CAF); 
vehicle+nicotine 1.5mg/kg (NIC); caffeine 40mg/kg+haloperidol 0.8mg/kg (CAF+HAL); nicotine 1.5mg/kg+haloperidol 0.8mg/kg (NIC+HAL). 
 
 
 
 
Figure 15. 
Figure 15. Intergroup differences in Homer1a mRNA expression among haloperidol, caffeine, and caffeine+haloperidol (left side) and among 
haloperidol, nicotine, nicotine+haloperidol (right side) in cortical (upper side) and striatal (lower side) ROIs. Data were reported in relative d.p.m. as 
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meanS.E.M. Lines connected groups whose mean mRNA expression was significantly different. * = significant difference at the Student-Newman-
Keuls post-hoc test (p<0.05).  
 
 2.1.2. Arc 
In the cortex, Arc transcript levels were significantly lower in HAL as compared to VEH. Nicotine 
treatment significantly decreased Arc expression in MC and IC regions compared to the control 
group, whereas caffeine provoked the same results only in the IC. CAF+HAL significantly reduced 
Arc mRNA expression in MC, SS and IC . To note, NIC+HAL, although not reaching statistically 
significance as compared to vehicle, was found to induce a slight, but significant, increase in Arc 
expression as compared to haloperidol.  
In the striatum, Arc mRNA expression was significantly higher in the  haloperidol treated group 
compared to the controls. Oppositely,  CAF significantly reduced gene expression in almost all 
subcortical regions. Notably, CAF+HAL  only induced significant decrease in Arc expression in 
ventro-medial caudate putamen and in the core region of the nucleus accumbens. Nicotine, when 
administered alone, resulted in no significant modifications of Arc gene expression, while NIC+HAL 
significantly increased Arc mRNA signal in medial striatal regions and in the nucleus accumbens. 
GBR-12909 specifically induced Arc gene expression in the nucleus accumbens core compared to 
the control group. 
All statistically significant results are detailed in Table 9. Significant differences as compared to 
vehicle are depicted in Figure 14., intergroup differences are graphed in Figure 16. 
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 ANOVA Post-hoc Test 
 F(df) p Student-Newman-Keuls Bonferroni 
ACC  ns   
MAC 2.92 6,18 0.03 
HAL < VEH p=0.02 
 
GBR > NIC p=0.02 
NIC+HAL > HAL p=0.03 
 
MC 7.41 6,18 0.0004 
HAL < VEH p=0.002 
NIC < VEH p=0.01 
CAF+HAL < VEH p=0.006 
 
CAF < GBR p=0.001 
NIC < GBR p=0.0002 
NIC+HAL > HAL p=0.02 
HAL < VEH p=0.02 
 
CAF+HAL < VEH p=0.04 
 
CAF < GBR p=0.007 
NIC < GBR p=0.001 
SS 2.77 6,18 0.04 
HAL < VEH p=0.008 
CAF+HAL < VEH p=0.04 
  
NIC+HAL > HAL p=0.02 
HAL < VEH p=0.05 
 
IC 3.19 6,18 0.02 
HAL < VEH p=0.002 
CAF < VEH p=0.04 
NIC < VEH p=0.007 
CAF+HAL < VEH p=0.01 
 
NIC+HAL > HAL p=0.02 
HAL < VEH p=0.01 
 
NIC < VEH p=0.05 
 
CP-DM 12.29 6,18 <0.0001 
HAL > VEH p=0.02 
CAF < VEH p=0.006 
NIC+HAL > VEH p=0.007 
 
CAF < GBR p=0.0001 
NIC < GBR p=0.01 
CAF < HAL p<0.0001 
CAF+HAL < HAL p=0.0002 
NIC < HAL p=0.002 
NIC < NIC+HAL p=0.0005  
 
CAF < VEH p=0.04 
NIC+HAL > VEH p=0.05 
 
CAF < GBR p=0.0007 
 
CAF < HAL p<0.0001 
CAF+HAL < HAL p=0.001 
NIC < HAL p=0.01 
NIC < NIC+HAL p=0.003 
CP-DL 5.11 6,18 0.003 
HAL > VEH p=0.04 
 
CAF < GBR p=0.007 
NIC < GBR p=0.03 
CAF < HAL p=0.0003 
CAF < CAF+HAL p=0.04 
CAF+HAL < HAL p=0.04 
NIC < HAL p=0.003 
NIC < NIC+HAL p=0.006 
 
 
CAF < GBR p=0.05 
 
CAF < HAL p=0.002 
 
 
NIC < HAL p=0.02 
NIC < NIC+HAL p=0.04 
CP-VM 12.61 6,18 <0.0001 
CAF < VEH p<0.0001 
CAF+HAL < VEH p=0.01 
NIC+HAL > VEH p=0.03 
 
CAF < GBR p<0.0001 
NIC < GBR p=0.002 
CAF < HAL p<0.0001 
CAF < VEH p<0.0001 
 
 
 
CAF < GBR p<0.0001 
NIC < GBR p=0.01 
CAF < HAL p<0.0001 
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CAF+HAL < HAL p=0.0006 
NIC < HAL p=0.008 
NIC < NIC+HAL p=0.0009 
CAF+HAL < HAL p=0.004 
NIC < HAL p=0.05 
NIC < NIC+HAL p=0.006 
CP-VL 8.82 6,18 0.0001 
HAL > VEH p=0.005 
CAF < VEH p=0.02 
 
CAF < GBR p=0.007 
NIC < GBR p=0.04 
CAF < HAL p<0.0001 
CAF < CAF+HAL p=0.04 
CAF+HAL < HAL p=0.0009 
NIC < HAL p<0.0001 
NIC < NIC+HAL p=0.001 
HAL > VEH p=0.03 
 
 
CAF < GBR p=0.05 
 
CAF < HAL p<0.0001 
 
CAF+HAL < HAL p=0.006 
NIC < HAL p<0.0001 
NIC < NIC+HAL p=0.007 
CAb 14.71 6,18 <0.0001 
HAL > VEH p=0.002 
GBR > VEH p=0.03 
CAF < VEH p=0.006 
CAF+HAL < VEH p=0.04 
NIC+HAL > VEH p=0.02 
 
CAF < GBR p<0.0001 
NIC < GBR p=0.004 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001 
NIC < HAL p=0.0002 
NIC < NIC+HAL p=0.001 
HAL > VEH p=0.01 
 
CAF < VEH p=0.04 
 
 
 
CAF < GBR p<0.0001 
NIC < GBR p=0.03 
CAF < HAL p<0.0001 
CAF+HAL < HAL p<0.0001 
NIC < HAL p=0.001 
NIC < NIC+HAL p=0.007 
SAb 5.79 6,18 0.002 
HAL > VEH p=0.008 
NIC+HAL > VEH p=0.007 
 
CAF < GBR p=0.03 
CAF < HAL p=0.0005 
CAF+HAL < HAL p=0.002 
NIC < HAL p=0.04 
NIC < NIC+HAL p=0.04 
HAL > VEH p=0.05 
NIC+HAL > VEH p=0.05 
 
CAF < HAL p=0.003 
CAF+HAL < HAL p=0.01 
 
 
Table 9. 
Table 9. Summarization of statistical data for Arc mRNA expression analysis. In this table, we provided statistical data outputs after quantification of 
relativized signal intensity of Arc mRNA expression in ISHH. Data have been listed for Regions of Interest as effect size (F), degrees of freedom (df), 
and two-tailed p level. In case of significant ANOVA, results of group pair’s comparisons at the Student-Newman-Keuls post-hoc test have been 
reported. Also, significant differences surviving Bonferroni’s correction were reported. Significant differences vs. vehicle have been given in italics, for 
clarity. 
Vehicle+vehicle (NaCl 0.9%, VEH); vehicle+haloperidol 0.8mg/kg (HAL); vehicle+GBR-12909 30mg/kg (GBR); vehicle+caffeine 40mg/kg (CAF); 
vehicle+nicotine 1.5mg/kg (NIC); caffeine 40mg/kg+haloperidol 0.8mg/kg (CAF+HAL); nicotine 1.5mg/kg+haloperidol 0.8mg/kg (NIC+HAL). 
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Figure 16. 
Figure 16. Intergroup differences in Arc mRNA expression among haloperidol, caffeine, and caffeine+haloperidol (left side) and among haloperidol, 
nicotine, nicotine+haloperidol (right side) in cortical (upper side) and striatal (lower side) ROIs. Data were reported in relative d.p.m. as meanS.E.M. 
Lines connected groups whose mean mRNA expression was significantly different. * = significant difference at the Student-Newman-Keuls post-hoc 
test (p<0.05). 
  
2.1.3.Homer1b 
In the cortex, Homer1b mRNA expression was significantly increased by GBR-12909 administration 
as compared to vehicle. Nicotine significantly induced Homer1b expression as compared to vehicle 
in ACC,  MC and SS, but NIC+HAL  provoked a broader significant overexpression of Homer1b in 
all cortical subregions, similarly to GBR-12909. No cortical impact was found by caffeine on 
Homer1b when administered alone, while CAF+HAL strongly induced the expression of the 
constitutive gene specifically in the MC region. NIC+HAL produced an elevation of Homer1b 
mRNA levels at a greater extent than the sole haloperidol throughout the cortex, whereas in SS and 
IC nicotine reduced the gene expression as compared to NIC+HAL.  
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In the striatum, Homer1b mRNA expression was significantly increased by GBR-12909 as compared 
to vehicle. Homer1b expression was also found induced by NIC  in the medial subregions of the 
caudate putamen and in the nucleus accumbens. NIC+HAL  also induced  Homer1b transcript by in  
the dorso-lateral caudate putamen in addition to the abovementioned regions. Nicotine significantly 
induced Homer1b expression in the nucleus accumbens compared to both GBR-12909 and 
haloperidol (Table 3). Caffeine had no significant effects as compared to vehicle on this constitutive 
gene in each striatal region taken into account. 
All statistically significant results are detailed in Table 10. Significant differences as compared to 
vehicle are depicted in Figure 14., intergroup differences are graphed in Figure 17. 
 
 ANOVA Post-hoc Test 
 F(df) p Student-Newman-Keuls Bonferroni 
ACC 4.17 6,19 0.008 
GBR > VEH p=0.005 
NIC > VEH p=0.01 
NIC+HAL > VEH p=0.006 
 
CAF < GBR p=0.01 
NIC > HAL p=0.01 
NIC+HAL > HAL p=0.007 
GBR > VEH p=0.03 
 
NIC+HAL > VEH p=0.04 
 
 
 
NIC+HAL > HAL p=0.05 
MAC 4.36 6,19 0.006 
GBR > VEH p=0.003 
NIC+HAL > VEH p=0.003 
 
CAF < GBR p=0.003 
NIC+HAL > HAL p=0.009 
GBR > VEH p=0.02 
NIC+HAL > VEH p=0.02 
 
CAF < GBR p=0.02 
NIC+HAL > HAL p=0.05 
MC 4.34 6,19 0.006 
GBR > VEH p=0.007 
CAF+HAL > VEH p=0.04 
NIC > VEH p=0.04 
NIC+HAL > VEH p=0.0008 
 
CAF < GBR p=0.02 
NIC+HAL > HAL p=0.003 
GBR > VEH p=0.05 
 
 
NIC+HAL > VEH p=0.005 
 
 
NIC+HAL > HAL p=0.02 
SS 5.92 6,19 0.001 
GBR > VEH p=0.004 
CAF+HAL > VEH p=0.008 
NIC > VEH p=0.02 
NIC+HAL > VEH p<0.0001 
 
CAF < GBR p=0.02 
CAF < CAF+HAL p=0.03 
NIC < NIC+HAL p=0.04 
NIC+HAL > HAL p=0.002 
GBR > VEH p=0.03 
CAF+HAL > VEH p=0.05 
 
NIC+HAL > VEH p<0.0001 
 
 
 
 
NIC+HAL > HAL p=0.01 
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IC 5.62 6,19 0.001 
GBR > VEH p=0.008 
NIC+HAL > VEH p<0.0001 
 
CAF < GBR p=0.03 
NIC < NIC+HAL p=0.01 
NIC+HAL > HAL p=0.0007 
GBR > VEH p=0.05 
NIC+HAL > VEH p<0.0001 
 
 
 
NIC+HAL > HAL p=0.005 
CP-DM 3.98 6,19 0.009 
GBR > VEH p=0.01 
NIC > VEH p=0.02 
NIC+HAL > VEH p=0.004 
 
CAF < GBR p=0.006 
NIC+HAL > HAL p=0.02 
 
 
NIC+HAL > VEH p=0.03 
 
CAF < GBR p=0.05 
 
CP-DL 2.82 6,19 0.04 
GBR > VEH p=0.01 
NIC+HAL > VEH p=0.04 
 
CAF < GBR p=0.003 
CAF < CAF+HAL p=0.05 
 
 
 
CAF < GBR p=0.02 
 
CP-VM 3.93 6,19 0.01 
GBR > VEH p=0.01 
NIC > VEH p=0.04 
NIC+HAL > VEH p=0.003 
 
CAF < GBR p=0.008 
NIC+HAL > HAL p=0.009 
 
 
NIC+HAL > VEH p=0.02 
 
CAF < GBR p=0.05 
NIC+HAL > HAL p=0.05 
CP-VL 2.61 6,19 0.05 
GBR > VEH p=0.01 
 
CAF < GBR p=0.005 
 
 
CAF < GBR p=0.03 
CAb 2.88 6,19 0.03 
NIC > VEH p=0.003 
NIC+HAL > VEH p=0.01 
 
NIC > GBR p=0.03 
NIC > HAL p=0.01 
NIC+HAL > HAL p=0.04 
NIC > VEH p=0.02 
 
 
 
SAb 4,26 6,19 0.007 
GBR > VEH p=0.04 
NIC > VEH p=0.0007 
NIC+HAL > VEH p=0.006 
 
NIC > GBR p=0.05 
NIC > HAL p=0.002 
NIC+HAL > HAL p=0.02 
 
NIC > VEH p=0.005 
NIC+HAL > VEH p=0.04 
 
NIC > HAL p=0.01 
 
 
Table 10. 
Table 10. Summarization of statistical data for Homer1b mRNA expression analysis. In this table, we provided statistical data outputs after 
quantification of relativized signal intensity of Homer1b mRNA expression in ISHH. Data have been listed for Regions of Interest as effect size (F), 
degrees of freedom (df), and two-tailed p level. In case of significant ANOVA, results of group pair’s comparisons at the Student-Newman-Keuls post-
hoc test have been reported. Also, significant differences surviving Bonferroni’s correction were reported. Significant differences vs. vehicle have been 
given in italics, for clarity.  
Vehicle+vehicle (NaCl 0.9%, VEH); vehicle+haloperidol 0.8mg/kg (HAL); vehicle+GBR-12909 30mg/kg (GBR); vehicle+caffeine 40mg/kg (CAF); 
vehicle+nicotine 1.5mg/kg (NIC); caffeine 40mg/kg+haloperidol 0.8mg/kg (CAF+HAL); nicotine 1.5mg/kg+haloperidol 0.8mg/kg (NIC+HAL). 
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Figure 17. 
Figure 17. Intergroup differences in Homer1b mRNA expression among haloperidol, caffeine, and caffeine+haloperidol (left side) and among 
haloperidol, nicotine, nicotine+haloperidol (right side) in cortical (upper side) and striatal (lower side) ROIs. Data were reported in relative d.p.m. as 
meanS.E.M. Lines connected groups whose mean mRNA expression was significantly different. * = significant differences at the Student-Newman-
Keuls post-hoc test (p<0.05).  
 
 
2.2. Protein Levels Analysis in Striatum 
Homer1a protein levels were significantly increased compared to basal levels by nicotine, alone or in 
association with haloperidol, and by caffeine plus haloperidol (Figure 18.). Protein levels by nicotine 
were also significantly higher than levels by GBR-12909 or haloperidol (SNK: p=0.0009 and 
p=0.002, respectively). Caffeine or nicotine addition to haloperidol significantly increased protein 
levels compared to haloperidol alone (SNK: p<0.0001 and p=0.004, respectively).  
Nicotine, alone or in association with haloperidol, and caffeine plus haloperidol were found to 
significantly increase Arc protein levels over basal ones (Figure 18.). Again, caffeine addition to 
haloperidol significantly increased protein levels compared to haloperidol alone (SNK: p=0.007). 
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Homer1b protein levels were unaffected (Figure 18.). 
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Figure 18. 
Figure 18. Measurements of Homer1a (left side) and Arc (right side) protein expression by Western Blot quantitation. Data are reported in relative 
intensity as means ± S.E.M. Student-Newman-Keuls post hoc test: * = vs. VEH (p<0.05). Homer1b protein levels were not depicted as they were not 
significantly different among groups.  
Vehicle+vehicle (NaCl 0.9%, VEH); vehicle+haloperidol 0.8mg/kg (HAL); vehicle+GBR-12909 30mg/kg (GBR); vehicle+caffeine 40mg/kg (CAF); 
vehicle+nicotine 1.5mg/kg (NIC); caffeine 40mg/kg+haloperidol 0.8mg/kg (CAF+HAL); nicotine 1.5mg/kg+haloperidol 0.8mg/kg (NIC+HAL). 
 
3. Behavioral Analysis 
In order to avoid possible biases induced in gene expression by novel environment stimuli, after the 
second injection each rat was re-placed, for 20 minutes before the locomotion assessment, in the 
same cage and with the same other animals with which it was allowed to become familiar during the 
housing and adaptation period, as well as during all the experiment procedures.  
Locomotor activity was significantly increased by GBR-12909 and decreased by haloperidol 
compared to vehicle-treated rats, as expected (Figure 6). Nicotine significantly reduced lomocotion 
compared to vehicle, either when given alone or in addition to haloperidol (Figure 19.). Notably, 
locomotor activity by nicotine plus haloperidol was significantly lower than by nicotine alone (SNK: 
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p=0.01), suggesting a reinforcing effect of haloperidol on nicotine as regard to impaired locomotion 
(Figure 19.). Caffeine did not reduce locomotor activity per se, however it did when given in 
addition to haloperidol (Figure 19.). Both nicotine and caffeine-mediated locomotor activity was 
significantly lower compared to that elicited by GBR-12909 (SNK: p<0.0001 either). On the 
contrary, caffeine-mediated locomotor activity was significantly higher than that by haloperidol 
(SNK: p=0.005).   
 
 
Figure 19. 
Figure 19. Locomotor activity measurement following each treatment. Data are reported in centimeters measuring the distance walked as means ± 
S.E.M. Student-Newman-Keuls post hoc test: * = vs. VEH (p<0.05). 
Vehicle+vehicle (NaCl 0.9%, VEH); vehicle+haloperidol 0.8mg/kg (HAL); vehicle+GBR-12909 30mg/kg (GBR); vehicle+caffeine 40mg/kg (CAF); 
vehicle+nicotine 1.5mg/kg (NIC); caffeine 40mg/kg+haloperidol 0.8mg/kg (CAF+HAL); nicotine 1.5mg/kg+haloperidol 0.8mg/kg (NIC+HAL). 
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CHAPTER 7 
 
Postsynaptic density protein transcripts are differentially modulated by minocycline alone or 
in add-on to haloperidol. 
 
1.Rationale 
 
Existing antipsychotics are only partially effective towards negative symptoms and cognitive deficits 
of schizophrenia (Dunlop and Brandon, 2015; Karam et al., 2010; Pratt et al., 2012; Stroup et al., 
2016). These data rise the issue of the urgent need of pro-cognitive therapeutic strategies. 
Interestingly, several case reports and clinical trials have reported therapeutic improvement in 
psychotic, negative, and cognitive symptoms by add-on therapies to antipsychotics with minocycline 
(Chaudhry et al., 2012; Chaves et al., 2010; Chaves et al., 2015; Ghanizadeh et al., 2014; Kelly et al., 
2011; Oya et al., 2014).  Therefore, minocycline has been proposed among the potential 
augmentation strategies in the treatment of poor responder and TRS  patients (Kelly et al., 2015; 
Qurashi et al., 2014). Nevertheless, preclinical studies on the molecular effects of minocycline 
administration on brain plasticity are still lacking. Indeed,  animal studies to date have only explored 
the behavioral effects of minocycline administration. For example, in mice and monkeys it has been 
shown that, in either dopaminergic or glutamatergic pharmacological models of psychosis-like 
behavior, minocycline administration could improve locomotor and behavioral abnormalities 
(Mizoguchi et al., 2008; Zhang et al., 2006a; Zhang et al., 2006b). Furthermore, minocycline has 
been found to revert cognitive visuo-spatial memory deficits and changes in sensorimotor gating in 
rats administered with the non-competitive NMDA receptor antagonist dizocilpine maleate (MK-
801) (Levkovitz et al., 2007). 
On the basis of the translational value of the research, we therefore investigated whether minocycline 
add-on to haloperidol may affect the expression of PSD transcripts known to play a relevant role in 
synaptic regulation, i.e. Homer1a, Homer1b and Arc (details for oligodeoxyribonucleotide probes 
have been listed in Table 11.).  
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Probe cDNA length (bp) cDNA position mRNA Gen-Bank# 
Homer1a 48 2527–2574 Homer1a U92079 
Homer1b/c 48 1306–1353 Homer1b/c AF093268 
Arc 45 789-833 Arc NM019361 
Table 11. 
Table 11. Probes for in situ hybridization histochemistry. 
 
The experimental paradigm comprised originally two groups of animals receiving a pre-treatment of  
vehicle (VEH; NaCl 0.9%) or  ketamine (KET; 30 mg/kg), in order to evaluate gene expression 
under physiological conditions and after the manipulation of the glutamatergic system. Specifically, 
the rationale of the pre-treatment stemmed from the idea of  mimicking  an acute “glutamatergic” 
psychosis compared to a “naturalistic” condition, and  ketamine was chosen among the other NMDA 
receptor antagonists since it has been widely used in pharmacological models of psychotic-like 
behaviors in preclinical studies (Lipska and Weinberger, 2000). Subsequently, animals (n=28 for 
each pre-treatment group) underwent the treatment step, where a second compound was administered. 
In the treatment step, animals were randomly subdivided in four subgroups in each pre-treatment arm 
(n=7 for each treatment group), and the evaluation of gene expression was obtained  after the 
administration of haloperidol  (HAL),  minocycline (MIN), or the combination of the two 
compounds (HAL+MIN) as compared with controls (VEH). An  i.p. injection 30 min after the pre-
treatment was performed for the administration of the second compound and animals were sacrificed 
90 min after the last injection. In the VEH pre-treatment arm, the following treatment groups were 
obtained:  (a) VEH+VEH (NaCl 0.9%, VEH+VEH); (b) VEH+HAL 0.8 mg/kg (VEH+HAL); (c) 
VEH+MIN 45 mg/kg (VEH+MIN); (d) VEH+HAL 0.8 mg/kg+MIN 45 mg/kg (VEH+HAL+MIN). 
In the KET pre-treatment arm, the following treatment groups were obtained: (a) KET+VEH; (b) 
KET+HAL 0.8 mg/kg (KET+HAL); (c) KET+MIN 45 mg/kg (KET+MIN); (d) KET+HAL 0.8 
mg/kg+MIN 45 mg/kg (KET+HAL+MIN).  
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Ketamine was administered at a sub-anaesthetic and sub-convulsant dose considered to mimic an 
animal model of acute psychosis (Lipska and Weinberger, 2000). Haloperidol was given at 
behaviourally active doses, known to elicit gene expression (Ambesi-Impiombato et al., 2007) 
Finally, minocycline was given at a dose reported to have neuroprotective effects according to 
previous published works (Adembri et al., 2014; Bye et al., 2007).  
Repeated measures ANOVA was used to analyze the individual contribution of each of the 
categorization factors on the outcome of gene expression that was considered the dependent variable. 
Pre-treatment and treatment effects and their interaction were investigated by between-subjects 
analysis, while within-subjects analysis investigated the ROI effect. Analyses of ROIs interaction 
with pre-treatment, treatment, and pre-treatment×treatment effects were also carried out (Table..). 
The SNK  post-hoc test with the Bonferroni correction was used for groups’ comparison. Post-hoc 
comparisons were carried out at each individual ROI level, for clarity, and separately among groups 
pre-treated by VEH and among groups pre-treated by KET. In case of significant between-subjects 
pre-treatment×treatment interaction, we also carried out comparisons among groups pre-treated by 
VEH vs groups pre-treated by KET. In all tests, significance was set at p<0.05 (two-tailed). The 
statistical analyses were performed using JMP9.0.1 and SPSS softwares. 
 
2.Results 
We observed that the expression of the IEGs Homer1a and Arc was significantly and differentially 
modulated by the psychoactive treatments administered. The major result obtained  was that 
minocycline add-on to haloperidol blunted the haloperidol-mediated expression of Arc gene, and 
specifically the add-on treatment significantly modified Arc mRNA expression in the cortex, while 
halopridol per se did not significantly affect gene expression in this area. 
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The second result was that Homer1a transcript expression underwent a significant treatment effect 
with also a significant region- dependent effect, as a confirmation of the observations reported in 
previous studies.   
Results are listed as gene expression changes observed for each transcript taken into account 
(Homer1a, Homer1b and Arc, respectively).  
 
2.1.Homer1a 
At the between-subjects analysis, only treatment administration showed a significant effect on 
Homer1a gene expression levels, while no significant effects of pre-treatment or of the pre-
treatment×treatment interaction were observed (Table 12.). At the within-subjects analysis, the 
consideration of the ROIs showed a significant effect on Homer1a mRNA expression levels (Table 
12.). Significant treatment×ROI and pre-treatment×treatment×ROI effects were found, while no pre-
treatment×ROI effect was found ( Table 12.).  
Among the VEH pre-treated groups, Homer1a expression levels were significantly higher in the  
VEH+HAL group as compared with VEH+VEH in the MC region of the cortex and in the entire 
caudate putamen (Figure20.; Table 13.). On the other side, no significant differences were observed 
between the VEH+MIN and VEH+VEH groups (Figure 20.), suggesting that MIN per se did not 
impact Homer1a mRNA levels. Finally, Homer1a was found significantly induced by 
VEH+HAL+MIN compared with VEH+VEH in the majority of the caudate putamen regions (Figure 
20.). 
Among the KET pre-treated groups, few significant differences were found, that substantially 
matched those found in the VEH pre-treated groups (Figure 20.).  
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Homer1a  Homer1b/c 
 
Arc 
Between-Subjects Effects Between-Subjects Effects Between-Subjects Effects 
Effect p-value 
F-
valuedf 
Effect 
p-
value 
F-
valuedf 
Effect p-value 
F-
valuedf 
Pre-
treatment 
0.64 0.221 
Pre-
treatment 
0.53 0.411 
Pre-
treatment 
0.95 0.011 
Treatment 0.003 6.233 Treatment 0.31 1.243 Treatment <0.0001 40.693 
Pre-
treatment* 
Treatment 
0.62 0.603 
Pre-
treatment* 
Treatment 
0.51 0.793 
Pre-
treatment* 
Treatment 
0.03 3.203 
Within-Subjects Effects Within-Subjects Effects Within-Subjects Effects 
Effect p-value 
F-
valuedf 
Effect 
p-
value 
F-
valuedf 
Effect p-value 
F-
valuedf 
ROI <0.0001 8.6610 ROI <.0001 22.0910 ROI <.0001 46.0510 
 
Table 12. 
Table 12. This table summarizes the outputs of repeated measures ANOVA for Homer1a, Homer1b/c, and Arc gene transcripts. Between-subjects 
effects were pre-treatment (either vehicle or ketamine). Within-subjects effects were regions of interest (ROIs; see Figure 2.). Significant values 
(p<0.05, two-tailed) are reported in bold. 
HAL: haloperidol; KET: ketamine; MIN: minocycline. 
 
 
Figure 20. 
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Figure 20. Autoradiograms of Homer1a expression and illustrative histograms of gene expression throughout cortical and striatal subregions. 
Upper panel: illustrative autoradiograms of Homer1a expression in cortico-striatal regions. Lower panels: levels of Homer1a mRNA expression (in 
relative dpm) for each cortical (upper side) and striatal (lower side) subregion. Histogram bars illustrate means±standard error of the mean (SEM). 
Significant inter-group differences have been depicted by solid lines connecting significantly different groups. 
ACC: anterior cingulate cortex; CAb: core of the nucleus accumbens; DL: dorsolateral caudate-putamen; DM: dorsomedial caudate-putamen; HAL: 
haloperidol; IC: insular cortex; KET: ketamine; MAC: medial agranular cortex; MC: motor cortex; MIN: minocycline; SAb: shell of the nucleus 
accumbens; SS: somatosensory cortex; VEH: vehicle; VL: ventrolateral caudate-putamen; VM: ventromedial caudate-putamen. 
 
Pre-Treatment VEHICLE 
Group 
Comparison 
HAL vs. VEH 
 
MIN vs. VEH 
 
HAL+MIN vs. VEH 
 
HAL+MIN vs. HAL 
p-value SNK Bonferroni SNK Bonferroni SNK Bonferroni SNK Bonferroni 
ACC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MAC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MC .01 .03 >.05 >.05 >.05 >.05 >.05 >.05 
SS .03 >.05 .02 >.05 >.05 >.05 >.05 >.05 
IC .001 .06 .004 >.05 .003 >.05 >.05 >.05 
DM .005 .03 >.05 >.05 .004 .002 >.05 >.05 
DL .003 .01 >.05 >.05 .01 .04 >.05 >.05 
VM .006 .009 >.05 >.05 .01 .04 >.05 >.05 
VL .0009 .001 >.05 >.05 .02 >.05 >.05 >.05 
CAb .01 .06 >.05 >.05 .03 >.05 >.05 >.05 
SAb .04 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
 
Pre-Treatment KETAMINE 
Group 
Comparison 
HAL vs. VEH 
 
MIN vs. VEH 
 
HAL+MIN vs. VEH 
 
HAL+MIN vs. HAL 
p-value SNK Bonferroni SNK Bonferroni SNK Bonferroni SNK Bonferroni 
ACC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MAC >.05 >.05 .03 >.05 .005 .06 >.05 >.05 
MC >.05 >.05 >.05 >.05 .006 >.05 >.05 >.05 
SS >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
IC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
DM >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
DL .03 >.05 >.05 >.05 .03 >.05 >.05 >.05 
VM >.05 >.05 .04 >.05 >.05 >.05 >.05 >.05 
VL .007 .05 >.05 >.05 >.05 >.05 >.05 >.05 
CAb >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
SAb >.05 >.05 .04 >.05 >.05 >.05 >.05 >.05 
 
Table 13. 
Table 13. Treatment group comparisons of Homer1a transcript expression. ACC: anterior cingulate cortex; CAb: core of the nucleus accumbens; DL: 
dorsolateral caudate-putamen; DM: dorsomedial caudate-putamen; HAL: haloperidol; IC: insular cortex; KET: ketamine; MAC: medial agranular 
cortex; MC: motor cortex; MIN: minocycline; SAb: shell of the nucleus accumbens; SNK: Student-Newman-Keuls; SS: somatosensory cortex; VEH: 
vehicle; VL: ventrolateral caudate-putamen; VM: ventromedial caudate-putamen. 
In this table are reported the p-values of the comparison among treatment groups (in order: HAL; VEH; MIN; HAL+MIN) throughout cortical and 
striatal regions of interest (ROIs). Comparisons were carried out by SNK with Bonferroni correction, separately among groups pre-treated with VEH 
and groups pre-treated with KET. Significant p-values (p<0.05, two-tailed) after Bonferroni correction are given in bold. In italics are provided p-
values that show a trend toward significance. 
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2.2. Homer1b 
At the between-subjects analysis, no significant effects of pre-treatment or treatment were observed 
on Homer1b gene expression levels (Table 12.) and no pre-treatment×treatment effect was found. At 
the within-subjects analysis, a significant ROI effect on Homer1b transcript expression values was 
found (Table 12.). Comparisons carried out, by SNK with Bonferroni correction, separately among 
groups pre-treated with VEH and groups pre-treated with KET did not show significant 
p-values (Table 14.; Figure 21.). 
 
 
Figure 21. 
Figure 21. Autoradiograms of Homer1b/c expression and illustrative histograms of gene expression throughout cortical and striatal subregions. Upper 
panel: illustrative autoradiograms of Homer1b/c expression in corticostriatal regions. Lower panels: levels of Homer1b/c mRNA expression (in relative 
dpm) for each cortical (upper side) and striatal (lower side) subregion. Histogram bars illustrate means±standard error of the mean (SEM). ACC: 
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anterior cingulate cortex; CAb: core of the nucleus accumbens; DL: dorsolateral caudate-putamen; DM: dorsomedial caudate-putamen; HAL: 
haloperidol; IC: insular cortex; KET: ketamine; MAC: medial agranular cortex; MC: motor cortex; MIN: minocycline; SAb: shell of the nucleus 
accumbens; SS: somatosensory cortex; VEH: vehicle; VL: ventrolateral caudate-putamen; VM: ventromedial caudate-putamen. 
 
 
Pre-Treatment VEHICLE 
Group 
Comparison 
HAL vs. VEH 
 
MIN vs. VEH 
 
HAL+MIN vs. VEH 
 
HAL+MIN vs. HAL 
p-value SNK Bonferroni SNK Bonferroni SNK Bonferroni SNK Bonferroni 
ACC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MAC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
SS >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
IC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
DM >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
DL >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
VM >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
VL >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
CAb >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
SAb >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
 
Pre-Treatment KETAMINE 
Group 
Comparison 
HAL vs. VEH 
 
MIN vs. VEH 
 
HAL+MIN vs. VEH 
 
HAL+MIN vs. HAL 
p-value SNK Bonferroni SNK Bonferroni SNK Bonferroni SNK Bonferroni 
ACC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MAC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
SS >.05 >.05 >.05 >.05 >.05 >.05 .02 >.05 
IC >.05 >.05 >.05 >.05 >.05 >.05 .02 >.05 
DM >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
DL >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
VM >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
VL >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
CAb >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
SAb >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
 
Table 14. 
Table 14. Treatment group comparisons of Homer1b/c transcript expression. ACC: anterior cingulate cortex; CAb: core of the nucleus accumbens; DL: 
dorsolateral caudate-putamen; DM: dorsomedial caudate-putamen; HAL: haloperidol; IC: insular cortex; KET: ketamine; MAC: medial agranular 
cortex; MC: motor cortex; MIN: minocycline; SAb: shell of the nucleus accumbens; SNK: Student-Newman-Keuls; SS: somatosensory cortex; VEH: 
vehicle; VL: ventrolateral caudate-putamen; VM: ventromedial caudate-putamen. 
In this table are reported the p-values of the comparison among treatment groups (in order: HAL; VEH; MIN; HAL+MIN) throughout cortical or 
striatal regions of interest. Comparisons were carried out, by SNK with Bonferroni correction, separately among groups pre-treated with VEH and 
groups pre-treated with KET. To note: no significant p-values were found. 
 
 
2.3. Arc 
At the between-subjects analysis, the  treatment effect was statistically significant, but no pre-
treatment effect was observed (Table 12.). However, a significant pre-treatment×treatment effect was 
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found. At the within-subjects analysis, a significant ROI effect on Arc mRNA expression levels was 
observed (Table 12.). Finally, a significant treatment×ROI interaction was also observed (Table 12.), 
with comparisons carried out separately in each ROI.  
Among the VEH pre-treated groups, VEH+HAL  treatment significantly induced Arc mRNA 
expression compared with VEH+VEH in all striatal regions (Figure 22.). Conversely, in the same 
regions, Arc mRNA expression was significantly reduced by VEH+MIN compared with VEH+VEH 
(Figure 22.).  Notably, Arc mRNA expression was significantly lower in rats treated with 
VEH+HAL+MIN compared with the VEH+VEH  and the VEH+HAL groups in almost all cortical 
regions and in almost all caudate putamen regions taken into account (Figure 22., Table 15.).  
Among the KET pre-treated groups, significant changes in Arc mRNA expression substantially 
matched the changes observed in VEH pre-treated groups (Table 4). However, no significant 
differences between KET+HAL+MIN and KET+HAL were observed (Table 15.). 
As in the case of Arc transcript a significant pre-treatment effect was found, differentially from 
Homer1a and Homer1b, a comparison between the groups pretreated with VEH and those pre-treated 
with KET was also carried out (Table 16.; for clarity, only corresponding treatments were compared). 
Arc mRNA expression was significantly lower in KET+HAL treated rats compared with VEH+HAL 
treated ones in the majority of the caudate putamen regions considered (Table 16.).  
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Figure 22. 
Figure 22. Autoradiograms of Arc expression and illustrative histograms of gene expression throughout cortical and striatal subregions. Upper panel: 
illustrative autoradiograms of Arc expression in corticostriatal regions. Lower panels: levels of Arc mRNA expression (in relative dpm) for each 
cortical (upper side) and striatal (lower side) subregion. Histogram bars illustrate means±standard error of the mean (SEM). Significant inter-group 
differences have been depicted by solid lines connecting significantly different groups. #: significantly different from the corresponding group that 
received vehicle as the pre-treatment. ACC: anterior cingulate cortex; CAb: core of the nucleus accumbens; DL: dorsolateral caudate-putamen; DM: 
dorsomedial caudate-putamen; HAL: haloperidol; IC: insular cortex; KET: ketamine; MAC: medial agranular cortex; MC: motor cortex; MIN: 
minocycline; SAb: shell of the nucleus accumbens; SS: somatosensory cortex; VEH: vehicle; VL: ventrolateral caudate-putamen; VM: ventromedial 
caudate-putamen. 
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Pre-Treatment VEHICLE 
Group 
Comparison 
HAL vs. VEH 
 
MIN vs. VEH 
 
HAL+MIN vs. VEH 
 
HAL+MIN vs. HAL 
p-value SNK Bonferroni SNK Bonferroni SNK Bonferroni SNK Bonferroni 
ACC >.05 >.05 >.05 >.05 .0003 .006 <.0001 .001 
MAC >.05 >.05 >.05 >.05 .001 .02 .0003 .003 
MC >.05 >.05 >.05 >.05 .003 .02 .001 .005 
SS >.05 >.05 >.05 >.05 .002 .005 .007 .02 
IC >.05 >.05 .01 >.05 .007 .05 >.05 >.05 
DM <.0001 .001 .004 .02 .004 .03 <.0001 .001 
DL <.0001 .001 .0007 .04 <.0001 .001 .001 >.05 
VM <.0001 .001 .002 .005 .04 >.05 <.0001 .001 
VL <.0001 .001 .009 .03 .0008 .001 .001 .004 
CAb <.0001 .001 .04 >.05 .01 >.05 .002 .009 
SAb <.0001 .001 .003 .04 .005 .07 .0003 .002 
 
Pre-Treatment KETAMINE 
Group 
Comparison 
HAL vs. VEH 
 
MIN vs. VEH 
 
HAL+MIN vs. VEH 
 
HAL+MIN vs. HAL 
p-value SNK Bonferroni SNK Bonferroni SNK Bonferroni SNK Bonferroni 
ACC >.05 >.05 >.05 >.05 .008 .01 >.05 >.05 
MAC >.05 >.05 >.05 >.05 .007 .01 >.05 >.05 
MC >.05 >.05 >.05 >.05 .003 .01 >.05 >.05 
SS .04 >.05 .007 .07 .0002 .001 .01 >.05 
IC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
DM .001 .002 .0004 .001 .01 .08 >.05 >.05 
DL .0004 .001 .0006 .001 .0003 .001 >.05 >.05 
VM .004 .03 .0002 .002 >.05 >.05 >.05 >.05 
VL .0002 .001 .0004 .001 .0005 .003 >.05 >.05 
CAb .005 .03 .01 >.05 .03 >.05 >.05 >.05 
SAb .008 .02 .009 .02 .02 .07 >.05 >.05 
 
Table 15. 
Table 15. Treatment group comparisons of Arc transcript expression. ACC: anterior cingulate cortex; CAb: core of the nucleus accumbens; DL: 
dorsolateral caudate-putamen; DM: dorsomedial caudate-putamen; HAL: haloperidol; IC: insular cortex; KET: ketamine; MAC: medial agranular 
cortex; MC: motor cortex; MIN: minocycline; SAb: shell of the nucleus accumbens; SNK: Student-Newman-Keuls; SS: somatosensory cortex; VEH: 
vehicle; VL: ventrolateral caudate-putamen; VM: ventromedial caudate-putamen. In this table are reported the p-values of the comparison among 
treatment groups (in order: HAL; VEH; MIN; HAL+MIN) throughout cortical or striatal regions of interest. Comparisons were carried out by SNK 
with Bonferroni correction, separately among groups pre-treated with VEH and groups pre-treated with KET. Significant p-values (p<0.05, two-tailed) 
after Bonferroni correction are given in bold. In italics are provided p-values that show a trend toward significance. 
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Group 
Comparisons 
VEH+VEH vs. 
KET+VEH 
 
VEH+HAL vs. 
KET+HAL 
 
VEH+MIN vs. 
KET+MIN 
 
VEH+HAL+MIN vs. 
KET+HAL+MIN 
p-value SNK Bonferroni SNK Bonferroni SNK Bonferroni SNK Bonferroni 
ACC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MAC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
MC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
SS >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
IC >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
DM >.05 >.05 <.0001 .001 >.05 >.05 >.05 >.05 
DL >.05 >.05 .005 .02 >.05 >.05 >.05 >.05 
VM >.05 >.05 .03 .01 >.05 >.05 >.05 >.05 
VL >.05 >.05 .03 >.05 >.05 >.05 >.05 >.05 
CAb >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
SAb >.05 >.05 >.05 >.05 >.05 >.05 >.05 >.05 
 
Table 16. 
Table 16. Pre-treatment effect in Arc transcript expression. ACC: anterior cingulate cortex; CAb: core of the nucleus accumbens; DL: dorsolateral 
caudate-putamen; DM: dorsomedial caudate-putamen; HAL: haloperidol; IC: insular cortex; KET: ketamine; MAC: medial agranular cortex; MC: 
motor cortex; MIN: minocycline; SAb: shell of the nucleus accumbens; SNK: Student-Newman-Keuls; SS: somatosensory cortex; VEH: vehicle; VL: 
ventrolateral caudate-putamen; VM: ventromedial caudate-putamen. This table summarizes the results of the comparison between groups 
pre-treated with VEH and groups pre-treated with KET. Only corresponding groups were compared. Statistical analysis was carried out by SNK with 
Bonferroni correction. Significant p-values after Bonferroni correction are given in bold. In italics are provided p-values that show a trend toward 
significance.
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CHAPTER 8 
 
 
1.Discussion  
In the first research protocol studied herein, we aimed to gain knowledge into the antipsychotic-induced 
PSD transcripts changes after chronic treatments with first and second generation antipsychotics (namely, 
haloperidol and olanzapine) compared to the multitargeting agent asenapine. The choice of the set of 
PSD molecules was based on the fact that they have all been reported to be responsive to antipsychotic 
treatments ((de Bartolomeis et al., 2013b; Iasevoli et al., 2011a; Iasevoli et al., 2011b), as well as found 
to directly or indirectly interact with each other mainly mediating postsynaptic mGluR5-dependent 
signaling (Bertaso et al., 2010; Tu et al., 1999; Zhang and Lisman, 2012). 
Specifically, the IEG Homer1a, which expression is linked to neuronal depolarization (Shiraishi-
Yamaguchi and Furuichi, 2007; Wang et al., 2015), was found significantly reduced by haloperidol 
(mostly at the 0.8 mg/kg dose)  in multiple cortical regions, possibly mirroring a reduced neuronal 
activation. Interestingly, both asenapine and olanzapine induced Homer1a at a significant higher 
extent when compared to haloperidol (Buonaguro et al., 2017a). To note, asenapine and olanzapine share 
a strong action on serotonergic receptor (Scheidemantel et al., 2015) and  their receptor-binding profile 
may tackle the dopamine-glutamate-mediated neurotransmission in the cortex differentially from 
haloperidol. Therefore, the different cortical expression patterns of Homer1a could reflect on a molecular 
level a broader receptor- binding profile and therefore a different action on the glutamatergic cortical 
neurotransmission of olanzapine and mostly of asenapine. On the other hand, in accordance with 
previous published results, haloperidol exerted the highest and asenapine the least induction of Homer1a 
in the striatum, where the gene expression has been reported to be strongly dependent on D2 receptors 
antagonism (de Bartolomeis et al., 2016; Iasevoli et al., 2011b; Iasevoli et al., 2010a). 
Almost all chronic antipsychotics tested herein reduced the IEG Arc in the cortex (Buonaguro et al., 
2017a). This result may suggest that lowering Arc expression may be a mechanism to increase post-
synaptic neuronal activation, given that the IEG expression has been related to glutamate-mediated 
neuronal activation (Kumar et al., 2012) and agonism at serotonin 5-HT2A receptors (Li et al., 2015). 
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Accordingly, Arc mRNA expression was particularly reduced by the highest dose of asenapine and by 
olanzapine, with both compounds being antagonists at 5-HT2A receptors (Bymaster et al., 1996; Tarazi 
and Neill, 2013; Xiberas et al., 2001). Indeed, asenapine, which is the most potent 5-HT2A antagonist 
among the three compounds, produced significantly higher Arc mRNA cortical levels than both 
olanzapine and haloperidol. On the other hand, in the striatum the IEG seemed to be under the regulation 
of potent D2 receptor blockade, since haloperidol significantly induced Arc gene at a higher extent 
compared to both asenapine and olanzapine.  
For what concerns the constitutive genes Homer1b, PSD-95, and Shank1, which are all implicated 
in synaptic architecture and plasticity, there is a lack of information in the literature concerning their 
modulation by different antipsychotics chronically administered. In the present study, they were found 
substantially reduced after chronic antipsychotic treatments (Buonaguro et al., 2017a). It could be 
suggested that a reduced expression of these transcripts may implicate that chronic antipsychotics 
mediate a re-arrangement of synaptic architecture in post-glutamatergic neurons, as previously observed 
for the case of PSD-95 protein levels after antipsychotic treatment (Fumagalli et al., 2008). Specifically, 
when considering inter-group differences among the antipsychotics tested herein, Homer1b and PSD-95 
expression was significantly increased by olanzapine and asenapine compared to haloperidol in all brain 
regions, while Shank1 expression by antipsychotics followed another pattern. In this latter case, no gross 
significant differences among antipsychotics were found in the cortex, while in striatum, differently from 
the other two constitutive genes, haloperidol and olanzapine significantly increased gene expression 
compared to the lowest dose of asenapine. To note, the expression of the constitutive genes  was found 
affected by the different haloperidol and asenapine doses tested herein, confirming  the hypothesis that 
the modulation of synaptic plasticity could be differentially tuned based on the dose of the compound (de 
Bartolomeis et al., 2015).  
Finally, with the evaluation of the relative ratio of Homer1a/Homer1b  expression, we aimed at  
addressing the question of whether different receptor profile and different doses of the same 
antipsychotic may change the relative ratio of the two Homer1 isomers. In cortical regions, haloperidol  
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was found to significantly shift the ratio toward Homer1b expression, and the shift toward the expression 
of Homer1b progressively grew in more cortical regions as the dose went from the lowest to the highest 
administered. Conversely, in the striatum all antipsychotics shifted the ratio at various degrees toward the 
expression of Homer1a. Therefore, it could be suggested that the different modulation by the 
antipsychotics studied herein of the inducible vs. the constitutive Homer1 isoforms may mirror a 
differential impact on postsynaptic plasticity, exerting Homer1a and Homer1b opposite actions 
(Kammermeier, 2008). 
Intriguingly, the IEGs tested herein appeared to be mostly regulated by the 0.5 mg/kg haloperidol and by 
the 0.05 mg/kg asenapine over the other doses of the respective compounds. This is in contrast with what 
observed in a previous acute paradigm of the same set antipsychotic given at the same dose-ranges (de 
Bartolomeis et al., 2015). Indeed, the acute paradigm previously realized showed that the expression of 
early and constitutive genes was significantly increased in cortical and sub-cortical regions by all 
antipsychotics used and at each dose .We therefore specifically investigated the expression pattern of the 
IEG Homer1a  comparing acutely versus chronically treated groups of animals.  
The results of the comparison suggested that the biological effects of antipsychotics may be attenuated 
after prolonged treatments and that the maximum modulation of gene expression may be obtained by the 
chronic administration of high doses of these compounds. Indeed, as the dose of the antipsychotic tested 
increased in both paradigms of administration, a progressive recruitment of more striatal and cortical 
regions was observed. Specifically, we found that increasing doses of haloperidol resulted in significant 
differences in acute versus chronic paradigms in a major number of cortical regions, while increasing 
doses of asenapine triggered differences in gene expression in a progressive major number of striatal 
regions. This final observation could be of particular translational meaning, since it could be speculated 
that chronic treatments exert very different effects when compared to acute ones, particularly 
topographically tackling distinct areas of the brain depending on the dose administered.  
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The third set of experiments aimed at the characterization of the molecular and behavioral effects of 
caffeine and nicotine in addition to haloperidol. The major results were that caffeine and nicotine per 
se were found not to widely affect mRNA expression at the PSD, while the scenario dramatically 
changed when their administration was followed by haloperidol. In the case of caffeine, the 
expression of the two IEGs  Homer1a and Arc was significantly reduced when its administration was 
followed by haloperidol compared to haloperidol alone, while protein levels were significantly 
increased compared to both basal and haloperidol-induced levels. These results may be  explained on 
the basis of  caffeine’s complex receptor interactions. It has been reported that at the presynaptic 
level, caffeine may preferentially block A2ARs over A1Rs on glutamatergic terminals (Ciruela et al., 
2006), which may increase glutamate release. At the postsynaptic level, caffeine antagonist action on 
A2ARs may reduce mGluR5 (Fuxe et al., 2003), which may increase D2 receptors activation. In our 
paradigm, D2 receptors activation may be  prevented by haloperidol blockade. The combined effect 
of glutamatergic activation and loss of D2 receptor-mediated inhibitory effect may explain why the 
combination of caffeine and haloperidol increased protein levels significantly more than caffeine or 
haloperidol alone, which did not increase Homer1a and Arc proteins compared to basal levels. On 
the other hand,  the observed reduction of mRNA expression may represent a feedback mechanism 
consequent to protein amount elevation or may depend on the blockade of post-receptor signaling 
cascades leading to Homer1a and Arc expression. Notably, it has been observed that A1Rs mediate 
Homer1a mRNA expression, at least in cortical areas (Serchov et al., 2015), where A1Rs are more 
abundant than A2ARs (Ferre and Sebastiao, 2016). Therefore, the significant reduction of Homer1a 
expression by caffeine addition to haloperidol in comparison to both basal levels and haloperidol-
induced levels may depend, at least in cortical areas, by caffeine antagonist action on A1Rs. This 
same mechanism may also account for increased Homer1b expression by caffeine plus haloperidol in 
cortical areas.    
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In the case of nicotine, gene expression was increased by nicotine in association to haloperidol. This 
effect may be mediated by a reinforcing action of haloperidol, which may boost the known dopamine 
and glutamate activation by nicotine (Sulzer, 2011). On the protein level, nicotine was found to 
increase protein levels for  example of Homer1a, and this results was observed also by other 
researches (Rezvani et al., 2007). Notably, Homer1a is known to counteract excessive NMDA 
receptor activation (Wang et al., 2015), and its increase may represent a neuronal feedback 
mechanism to prevent over-activation.  
Intriguingly, in all treatments where there was found an increase of Homer1a protein levels, a 
concomitant reduction of locomotor behavior was observed. In a previously published study, 
transgenic mice overexpressing Homer1a protein in striatum were associated to decreased locomotor 
activity in the open field test compared to wild-type littermates (Tappe and Kuner, 2006).. Notably, 
caffeine- and nicotine-induced locomotion was significantly higher than that induced by haloperidol 
alone, mostly as a result of the hypokinetic effects of haloperidol, rather than to a combined effect of 
the associations.   
Taken together, these data showed that caffeine and nicotine per se exert minor molecular effects on 
PSD molecules implicated in synaptic plasticity, schizophrenia pathophysiology, and antipsychotic 
treatment. However, these substances strongly affect haloperidol-mediated effects on these same 
molecules, with putative relevant pharmacological and clinical consequences potentially affecting 
treatment response and resistance to antipsychotics. 
 
In the final set of experiments, the expression profile of  the two IEGs Homer1a and Arc, together 
with  the constitutive gene Homer1b, were evaluated in the context of a newly proposed  
pharmacologic treatment consisting of minocycline add-on to antipsychotics in a preclinical model. 
In this study,  two pre-treatment  groups were tested:  drug-naïve (i.e. vehicle-pre-treated) rats versus 
ketamine-pre-treated rats. Indeed,  ketamine has been reported to induce behavioral and 
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neurochemical outcomes reminiscent of psychosis (Iasevoli et al., 2014a; Krystal et al., 1994; 
Newcomer et al., 1999) and according to previously published reports, acute ketamine administration 
can be regarded as a valuable and heuristic preclinical model of psychosis (Lipska and Weinberger, 
2000).  
The main findings of this set of experiments was that the above mentioned IEGs were significantly 
and differentially modulated by the psychoactive treatments administered, while no effects of the 
different pharmacological manipulations were observed in regards to the constitutive Homer1b gene 
(Buonaguro et al., 2017b). 
Particularly, it was observed that minocycline add-on to haloperidol blunted the haloperidol-
mediated expression of Arc gene in both cortical and subcortical regions. These results could suggest 
that minocycline add-on to haloperidol could impact the glutamate signaling pathway through the 
modulation of Arc gene expression. Indeed, Arc has been found to promote the endocytosis of 
AMPA receptors (Chowdhury et al., 2006; Shepherd and Bear, 2011), while the compound tested 
herein has been found to increase membrane localization and phosphorylation of AMPA  receptor 
(Imbesi et al., 2008), which turns in an increase of glutamatergic activity and modulation of 
neuroplasticity (Wang et al., 2005). Since Arc expression was reduced by minocycline when the 
compound was given as an add-on,  the combination with antipsychotics may potentiate 
minocylcine-mediated effects on AMPA-dependent glutamate signaling. To note, mice lacking 
GluR1 AMPA receptors have been reported to exhibit schizophrenia-like behaviors (Wiedholz et al., 
2008), and drugs that act as positive modulators of these receptors have been repoted to show 
precognitive effects and have been proposed as therapeutic strategies for schizophrenia (de 
Bartolomeis et al., 2012; Woolley et al., 2009). These observations may be regarded as a putative 
molecular rationale for the reported pro-cognitive action of minocycline when given as an add-on to 
antipsychotics (Levkovitz et al., 2010). 
Conversely, in the case of Homer1a, the administration of minocycline as an add-on to haloperidol  
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did not shown to impact Homer1a mRNA levels differentially from the administration of haloperidol 
alone. As already stated before, Homer1a expression has been found to be elicited by glutamatergic 
and dopaminergic stimuli with a key role in synaptic downscaling and reduction of neural 
excitability (Hu et al., 2010; Li et al., 2013; Siddoway et al., 2014). Nevertheless, it could be 
speculated that that the antibiotic tested herein alone and in combination with a first-generation 
antipsychotic impacts the architecture of the synapse more likely acting on Arc signaling pathway 
rather than on the Homer family of transcripts. Indeed, the results of the present study show that 
Homer1b mRNA levels were not modulated by the treatments tested herein.  
These results may represent the first step in elucidating potential changes of postsynaptic molecules 
after minocycline treatment in naïve and ketamine pre-treated animals (Buonaguro et al., 2017b). 
Minocycline may exert complex molecular actions on glutamate receptors and their post-synaptic 
effectors.  In general, minocycline has been reported to reduce NMDA receptors-mediated 
transmission and may reinforce AMPA receptors- and possibly mGluR-mediated signaling, which 
may have a ‘recovering’ effect on the glutamatergic synapse, in conditions of excitotoxicity or 
NMDA receptor blockade, respectively. These effects could be mirrored by the activation of specific 
intracellular signaling pathways, as that of Arc, and the modulatory action of minocycline on 
glutamatergic transmission may support, from a molecular point of view, its use in combination with 
conventional antidopaminergic compounds in TRS patients (Kelly et al., 2015; Oya et al., 2014; 
Qurashi et al., 2014). 
 
2.Concluding remarks 
With respect to the pathogenesis and treatment, schizophrenia and psychoses in general still remain 
'the big enigma of psychiatry' (O'Tuathaigh et al., 2017; Pull, 1981). Among the different 
methodologies possibly being applied to the study of the biological aspects of the disease, research 
on PSD molecules modifications may represent one possibility to elucidate synaptic remodeling 
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processes at least after psychotropic drugs administration. PSD are placed at crucial crossroads for 
multiple receptor signaling involved in the mechanisms of action of the most frequently used 
psychopharmacologic drugs and their close intermingling receives, elaborates, and converges 
multiple signals to the appropriate nuclear targets, in order to finely modulate synaptic 
rearrangements in response to neural activity. However, PSD molecular mechanisms are so 
sophisticated and complex that their knowledge is only partial at the moment.  
In the present work,  we have pointed out that dose and duration of antipsychotics administration 
impact differentially the level and topography of these molecules expression, further reinforcing the 
concept of an essential role of PSD molecules in dendritic spines morphologic changes induced by 
long-term antipsychotic treatment (Buonaguro et al., 2017a; Buonaguro et al., 2017b). The 
administration of substances such as caffeine and nicotine together with the well-characterized first 
generation antipsychotic haloperidol also gave interesting results in terms of differential quantitative 
and spatial modulation of key PSD transcripts and proteins, with also different effects on behavioral 
outcomes. Moreover, the evaluation of the pattern of expression of PSD molecules has also been 
suggested to provide information on augmentation or association strategies. Indeed, we have shown 
that Arc expression is differentially modulated by haloperidol alone, or in association with 
minocycline, the synthetic second-generation tetracycline recently proposed as an adjunctive 
treatment mostly for negative symptoms of schizophrenia. 
Overall, these reports suggest that PSD molecules are key actors in the mechanisms of action of 
psychotropic agents and their modulation may represent one of the ultimate biological steps 
responsible of pharmacological effects of these drugs. In these terms, PSD molecule modulation may 
characterize other recently proposed therapeutic agents (for example, the ones that act on 
glutamatergic transmission, such as: agonists at group 2/3 metabotropic glutamate receptors; positive 
allosteric modulators of type 5 metabotropic glutamate receptors; NMDA receptor modulators; 
AMPAkines; or glycine transporter inhibitors). Notably, despite multiple technical concerns, some 
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recent clinical and preclinical studies have investigated the efficacy of cell permeable peptides (CPP) 
and small peptide inhibitors (SPI), which may specifically interact with PSD proteins, such as PSD-
95 (Bach et al., 2012; Cook et al., 2012). 
Thanks to the observations obtained so far on PSD molecules ‘role in dopamine-glutamate interplay 
and their modulation after current therapeutics and other psychotropic drugs, further studies will 
putatively permit the development of “synapse-targeting” pharmacological strategies, which could 
finally and possibly target the resistant symptoms domains poorly impacted by available 
psychopharmacologic treatment. 
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